The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

5-2013

The Role Of IL-8-Mediated Src Family Kinase Activation In TumorTumor And Tumor-Stromal Interactions In Metastasis Of Prostate
Cancer
Lynnelle Thorpe

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Medical Sciences Commons

Recommended Citation
Thorpe, Lynnelle, "The Role Of IL-8-Mediated Src Family Kinase Activation In Tumor-Tumor And TumorStromal Interactions In Metastasis Of Prostate Cancer" (2013). The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open
Access). 342.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/342

This Dissertation (PhD) is brought to you for free and
open access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

THE ROLE OF IL-8-MEDIATED SRC FAMILY KINASE ACTIVATION IN
TUMOR-TUMOR AND TUMOR-STROMAL INTERACTIONS IN
METASTASIS OF PROSTATE CANCER
By
Lynnelle Thorpe, M.S.
APPROVED:

_______________________________________
Gary E. Gallick, Ph.D., Supervisory Professor

_______________________________________
Menashe Bar-Eli, Ph.D.

_______________________________________
Varsha V. Gandhi, Ph.D.

_______________________________________
Scott E. Kopetz, M.D.,Ph.D.

_______________________________________
Nora M. Navone, Ph.D.

APPROVED:

_______________________________________
Dean, The University of Texas
Graduate School of Biomedical Sciences at Houston

THE ROLE OF IL-8-MEDIATED SRC FAMILY KINASE ACTIVATION IN
TUMOR-TUMOR AND TUMOR-STROMAL INTERACTIONS IN
METASTASIS OF PROSTATE CANCER

A
DISSERTATION
Presented to the Faculty of
The University of Texas
Health Science Center at Houston
And
The University of Texas
M.D. Anderson Cancer Center
Graduate School of Biomedical Sciences
in Partial Fulfillment
of the Requirements
for the Degree of
DOCTOR OF PHILOSOPHY

by
Lynnelle Thorpe, MS
Houston, TX

May 2013

DEDICATION
To God, for giving me the ability and strength to pursue and finish this degree.
To my mother and father, Sheila L. and Willie H. Thorpe, and my sister, Alexia C. Lee,
for always believing in me and supporting me in all of my endeavors.

~ iii ~

ACKNOWLEDGEMENTS

I would like to express my deepest gratitude to my mentor, Dr. Gary E. Gallick, for his
tireless support, patience and encouragement during the duration of this degree. I am
especially appreciative of his mentorship and his diligence in training me.

I would also like to thank my committee members, Drs. Menashe Bar-Eli, Scott E.
Kopetz, Nora M. Navone and Varsha V. Gandhi, for their suggestions, ideas and their
continued support of me in attaining this degree.

I would like to thank all the members of Dr. Gallick’s laboratory, Nila U. Parikh, JungKang Jin, Tanushree Chatterji, Sanchaika Gaur, Andreas Varkaris, Rachel Harris and
Jian H. Song for their help, for always being ears to listen and for giving me
encouraging words.

~ iv ~

THE ROLE OF IL-8-MEDIATED SRC FAMILY KINASE ACTIVATION IN
TUMOR-TUMOR AND TUMOR-STROMAL INTERACTIONS IN
METASTASIS OF PROSTATE CANCER
Publication No.____________________
Lynnelle Thorpe, M.S.
Supervisory Professor: Gary E. Gallick, Ph.D.

Men with localized prostate cancer (PCa) have a 100% five-year survival rate,
but this rate drops to 33% for men with metastatic disease. A better understanding of
the metastatic process is needed to develop better therapies for PCa. Aberrant activation
of protein tyrosine kinases, including Src Family Kinases (SFKs) contribute to
metastasis through numerous functions, one of which leads to increased expression of
cytokines, such as IL-8. However, the relationship between Src activity and IL-8
regulation is not completely understood. In cell line models, I determined that IL-8
activates Src and in turn Src activates IL-8 demonstrating a feed forward loop
contributing to the migration and invasion of PCa cells.
However, IL-8 is also produced by tumor-associated stromal cells.

In bone

marrow derived stromal cells (HS5), I demonstrated a feed forward loop occurs as was
observed in tumor cells. HS5 conditioned media increased Src activity in PCa cells. By
silencing IL-8 in HS5 cells, Src activity was decreased to control levels in PCa cells as
was migration and invasion. Thus, stromal cells producing IL-8 contribute to metastatic
properties of PCa by a paracrine mechanism.
To examine the effect of stromal cells on tumor growth and metastatic potential
of PCa in vivo, I mixed HS5 and PCa cells and co-injected them intraprostatically. I
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determined that tumor growth and metastases were increased. By silencing IL-8 in HS5
cells and co-injecting them with PCa cells intraprostatically, tumor growth and
metastases were still increased relative to injection of PCa cells alone, but decreased
relative to co-injections with PCa cells and HS5 cells.
These studies demonstrated: (1) a feed forward loop in both tumor and stromal
cells, whereby IL-8 activates Src, derepressing IL-8 expression in PCa cells in vitro; (2)
stromal produced IL-8 activates Src and contributes to the migration and invasion of
PCa cells in vitro; and (3) stromal produced IL-8 is responsible, in part, for increases in
PCa tumor growth and metastatic potential.
Together, these studies demonstrated that IL-8-mediated Src activity increases
the metastatic potential of PCa and therapeutic agents interfering with the IL-8/SFK
signaling axis may be useful for prevention and treatment of metastases.
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CHAPTER 1
INTRODUCTION

~1~

OVERVIEW OF PROSTATE CANCER
Prostate cancer (PCa) is the most common cancer in men in the United States
and is the second leading cause of cancer mortality in western civilization. It is
estimated that that there will be 241,740 new cases and 28,170 deaths in 2012 (1). The
incidence of disease increases with age and as many as 35% of men ages 60-69 years
old and 46% of men ages 70-81 years old will develop PCa (2,3). When diagnosed
early, the 5-year relative survival rate for men with localized disease is nearly 100%,
but when disease is no longer organ confined, the 5-year survival rate for men
dramatically drops from nearly 100% to 29% (4). For localized disease, patients
initially respond to the front-line androgen ablation or surgical castration therapies, but
many patients progress to castration resistant prostate cancer (CRPC) where mortality
increases. The increased mortality is due, in part, to sustained androgen receptor
signaling.
Although recent therapies, discussed in detail in the current therapies section,
have been developed that more effectively block androgen synthesis or inhibit androgen
binding to AR, there are patients that still progress and eventually die (5-7). This
suggests that other mechanisms, in conjunction with AR signaling, must be explored in
CRPC. This also suggests that there are differences, either morphologically,
mechanistically or biologically, associated with stages of PCa development. In light of
this, we must first understand the current theories of how PCa develops and progresses
to CRPC which will be discussed in the next sections.
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DEVELOPMENT OF THE PROSTATE
To better understand the development of PCa, we must understand the
morphology and organization of the prostate. The prostate is a small walnut size organ
sitting below the bladder, posterior to the pubic bone and anterior to the rectum.
Comprised of ~70% glandular tissue and 30% muscular tissue, the prostate houses an
epithelial and stromal compartment separated by a basement membrane (8). The
normal prostate gland comprises three cell types: luminal, basal and neuroendocrine
cells. (Figure 1) The origin of each cell type is thought to develop from presumed
prostate stem cells, located in the basal layer and proximal ducts of the prostate gland,
which become differentiated and can be identified by their position, cell-type specific
markers and function (9).
The luminal cell layer, composed of columnar epithelial cells and located in
the lumen of the prostate, expresses the AR and prostate specific antigen (PSA), while,
functionally, it secretes seminal fluids. The basal cells, located in the basal layer of the
prostate gland, express low levels of AR, cytokeratins and cell adhesion molecules
(CAMs), while, functionally, separating the stromal compartment from the luminal cells
(10). The neuroendocrine cells, which express various basal cell markers, are unevenly
distributed within the basal layer representing a post-mitotic population of cells. In
addition, there is a stromal compartment that represents a cellular niche containing
mesenchymal and fibroblastic cells as well as lymphocytes, endothelial cells,
myofibroblasts and pericytes required to support the prostate for survival.
Androgen expression is a critical characteristic of prostate development.
Androgen signaling occurs through the AR supporting survival of the prostate. AR
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Figure 1
Histological Architecture of the Prostate
The normal epithelium consists of a luminal cells enveloped by a basal cell layer. The
stromal cell compartment is the outermost portion of the prostate epithelium.
Neuroendocrine cells are a post-mitotic cell type that can result transform into prostate
cancer.
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serves as a ligand-dependent transcription factor that, in the absence of ligand binding,
is distributed diffusely throughout the cytoplasm bound to heat shock proteins in an
inactive state. Ligand binding to the AR facilitates dimerization and nuclear
translocation where AR dimers bind to androgen response elements (AREs) stimulating
transcription of androgen regulated genes, such as KLK3, the gene encoding PSA
protein (11-12). As a result, PSA, serine protease protein secreted by prostate, as a
marker of AR function is widely used to assess prostate-specific AR activity (13-14).
Although controversial, PSA screening methods are utilized to monitor disease
progression and response to therapeutic intervention.
Thus far, we have described prostate development in terms of organization,
anatomy and androgen regulation. McNeal provides a well-accepted theory assessing
the anatomy of the prostate as a means to understand the regions of PCa development.
McNeal describes two zones of the prostate: the peripheral and the transition zone. The
peripheral zone, localized in the posterior portion of the gland, is considered the
primary site where PCa develops and accounts for ~75% of the region where PCa
originates. The transition zone, localized near the urethra, accounts for origination of
~20% of cancers, a less frequent site of cancer development (8,15).
Benign Prostate Hyperplasia
Benign prostate hyperplasia (BPH) represents a clinically significant
pathologic process that the prostate undergoes, but is not considered a precursor of PCa.
BPH is characterized by cellular proliferation and gland enlargement mainly in the
periurethral and transition zones of the prostate. Considered to be a normal process for
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aging men, only 10% of men with BPH require medicinal treatment making this
condition treatable and curable (16).
DEVELOPMENT OF PROSTATE CANCER
Prostate Stem Cells
PCa arises from cancer stem cells (CSCs), but there is controversy as to
whether the stem cell of origin is basal or luminal (17,18). The evidence that PCa
arises from luminal cells is due to the presence of non-terminally differentiated
secretory luminal cells along with minimal presence of basal cells and basal cellmarkers (19). This theory is also supported by the expression of luminal cell markers,
such as cytokeratins 8 and 18 (CK8 and 18), PSA, stem cell antigen-1 (Sca1) and
prostate stem cell antigen (PSCA) in cancer cells (9,18,20-23). In addition, Liao et al.
report that cancer stem cell differentiation to a luminal cell lineage also requires the
presence of the microenvironment suggesting that determining the stem cell origin is
further confounded by interactions with the microenvironment (24).
There is also evidence supporting the theory that PCa arises from a basal cell
origin (25). Studies report that a small population of cells in the prostate tumor express
basal markers, such as p63, hTERT and Bcl-2 (21,26). However, it is not clear whether
there is a conversion between basal and luminal stem cells leading to the development
of PCa. Wang et al. discuss two newer theories where, 1) there may be overlap in stem
cell activities such that the basal and luminal cells have autonomous progenitors or 2)
PCa arises from a basal cell progenitor that differentiates into luminal progenitor cells
(27). These studies highlight that there are still confounding questions about the true
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stem cell origin of PCa and what role the microenvironment plays, but it does shed light
on possible mechanisms of tumor initiation (19).
Prostatic Intraepithelial Neoplasia
Prostatic intraepithelial neoplasia (PIN) is suggested to occur under two
models- the stem cell hypothesis where transforming events in stem cells occur or by
the stochastic model where PIN develops from any cell harboring specific gene
mutations (28). The stem cell model is considered to be the most accepted model of
PIN initiation. PIN, first identified by Bostwick and Brawer, is defined as highly
proliferative epithelial cells, usually non-invasive, located within the normal prostatic
acinar ducts exhibiting large acini (29). There are two types of PIN- low grade
(LGPIN) and high grade (HGPIN) with different clinical outcomes. While LGPIN,
usually, does not progress to PCa and is less reported, HGPIN represents the earliest
recognized stage of carcinogenesis (30,31). Multiple studies report an increased
frequency of HGPIN in prostates with PCa and, amongst other highly significant
predictors of cancer, HGPIN ranks as having the highest risk ratio making it a marker
with high predictive value for PCa development (31-33).
There are multiple progressive morphological, genetic and phenotypic changes
associated with HGPIN in the progression to PCa, but some are also observed in PCa.
Some morphological changes involve the presence of dysplastic epithelial cells with an
enlarged nucleus and the disappearance of a defined basal cell membrane, although the
presence of basal cells still exist (31). Some progressive genetic and phenotypic
alterations associated with HGPIN, also observed in PCa, are decreased expression of
genes, such as the NKX3.1 and p27 genes, while there are also decreases associated
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with some genes involved in secretory differentiation, such as PSA and prostatic acid
phosphatase. There is also an increase in other genes, such as b-cell lymphoma 2 (bcl2), p53 and c-met (34-35). Along with morphological, phenotypic and genotypic
changes, multiple studies demonstrate that there is an observance of PIN lesions within
close proximity of malignant disease suggesting, at least morphologically, that PIN is a
pre-neoplastic condition to PCa (36). PIN is best distinguished from PCa by its organconfined phenotype and the inability of cells to become invasive.
Progression to Prostate Cancer
The transition from PIN to PCa involves progressive phenotypic and genotypic
changes, mentioned above, but there is also evidence suggesting that androgen signaling
is involved in the initiation of PIN and development of PCa (37). The initial survival
and dependence of PCa is due in large part to the presence of androgens. One of the
most predominant androgens found in the sera of males, testosterone, is converted by
the steroid 5α-reductase type 2 (SRD5A2) into a higher affinity androgen, 5αdihydrotestosterone (5α-DHT) in men with PCa (38). The subsequent binding of
androgen to AR, as described earlier, results in the transcription of androgen-regulated
genes that facilitate survival and proliferation. Huggins and Hodges provided some of
the earliest studies demonstrating that androgens increase PCa cell growth leading to the
development of multiple endocrine therapies (39). Androgen ablation therapies, such as
biclutamide, flutamide and leuprolide, were introduced to control disease (40). Patients
respond to these therapies and a small subset of patients are cured, but many progress
suggesting that AR is sustained and signaling still occurs (40-42). When patients
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become resistant to this treatment, this disease is termed castration resistant prostate
cancer (CRPC) and life expectancy drops.
Sustained signaling through AR, despite androgen ablation, is a major
consequence of CRPC. In an effort to understand the mechanisms underlying androgen
activity and the AR in CRPC, multiple in vitro and in vivo models have shown that,
even in the absence of androgen regulation, cells still express androgen-responsive
genes as well as AR (43-47). In fact, many cases of CRPC display aberrant AR activity
due to changes, such as amplifications, splice variants and/or altered AR target genes
(45,48,49). This suggests that CRPC utilizes a mechanism that bypasses the need for
androgen without deregulation of AR. There are additional mechanisms, outlined
below, that have been postulated describing reasons for aberrant activity of AR in
CRPC.
One mechanism suggests that AR is active due to alternate sources of
androgen, such as circulating dehydroepiandrosterone (DHEA) by the adrenal glands
(50-52). Other mechanisms suggest that increased AR sensitivity to low androgen
levels creates a hypersensitive mechanism, while increased levels of coactivators can
also enhance AR sensitivity, but to androgen and non-androgen ligands (53,54). Nonandrogen factors and non-androgen steroid hormones, such as estrogens and cortisol,
are also thought to be responsible for sustained AR activity through promiscuous ligand
binding (55). In conjunction with promiscuous ligand binding, studies demonstrate that
AR activation is also achieved through growth factor and/or receptor tyrosine kinase
pathways, such as IGF, HER-2/neu and Src, creating, what is commonly termed as an
outlaw mechanism (56-57). Studies suggest that steroid-induced Src, a non-receptor
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tyrosine kinase, activation results in association with AR stimulating signaling cascades
that regulate metastatic events, such as proliferation and migration (53,59). This further
suggests that, in CRPC where there is aberrant AR activity, Src activation may be a
contributing factor, which will be discussed in detail later (59). Although all the
mechanisms, albeit important in understanding the role of the AR in CRPC, are not
mutually exclusive and may work together to sustain CRPC, more studies are needed
addressing pathways that may lead to metastatic disease.
Metastatic Disease
While PCa, when detected at an early stage in patients, results in curable
disease, its progression to CRPC can lead to aggressive and metastatic disease.
Metastatic disease comprises distant metastases confined to the spleen, liver and, most
frequently, the bone and lymph nodes. Bubendorf et al. report that 80% of men dying
from PCa incurred bone metastases suggesting that metastatic sites offer a host of
factors that support the growth and survival of PCa (60). Paget’s ‘seed and soil’
hypothesis, explaining the cross-talk between cancer cells and organ-specific
microenvironments, is widely accepted as a model for understanding the
interdependency of tumor cells and cells in their metastatic microenvironment and
strongly suggests that organ-specific metastases require the metastatic ‘soil’ for
continued tumor growth (61,62). Thus, understanding the metastatic process involved
in cancer progression is important and we now understand that the biological
aggressiveness of metastatic disease is vastly a result of interactions between PCa cells
and their microenvironmental changes, increasing interest in studies that interrogate
organ-specific metastases.
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In an effort to understand the nature of how the microenvironment affects PCa,
Kaplan et al. describe site-specific niches that exist to support tumor cells in their
passage to distant sites and upon their arrival at the distant site, such as the primary
tumor, vascular, osteoblastic and pre-metastatic niches (63). It has been further
suggested that the preferential metastasis of PCa to specific organs is due, in part, to
heterotypic cell interactions, but there may be modifications to distant tissue sites which
prime the “soil” for cancer cells yielding a “pre-metastatic” niche (64). The premetastatic niche consists of immigrant and resident cells that “prime” the soil through
signaling mechanisms conducive to tumor seeding (63,65,66). An example of a
resident cell that may prime the “soil” are stromal cells. The bidirectional activities
between stromal cells and PCa cells provides a host of factors which contribute to
progression of metastatic disease (67,68).
Although there is ample evidence suggesting that bidirectional activities at the
primary site contribute to PCa growth and survival, there has been increased interest in
understanding the stromal-epithelial crosstalk at the metastatic site (69-71). Part of the
reasoning is that, even though the genetic and molecular changes in tumor cells are
required during tumor progression, they are not sufficient to fully drive tumors to be
metastatic. As a result, studies suggest that the metastatic potential of PCa is a stromadependent event and the balance of stromal factors within the metastatic tissue
determines metastatic behavior (43,72,73). This aspect is integral to the studies of my
thesis.
The role of the stroma in metastatic disease involves factors, such as
interleukin-6 (IL-6), CXCL-12, transforming growth factor beta (TGF-β), vascular
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endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs), that initiate
signaling cascades increasing metastatic properties of PCa (74,75). This reciprocal
signaling mechanism is thought to permit the promotion of metastasis to the host
environment. More recent, in vivo and in vitro, studies support the hypothesis that
organ-specific PCa cell and stromal interactions contribute to a “vicious cycle” whereby
the stroma modifies the PCa cells and the PCa cells modify the stroma (76-78).
Increasing evidence suggests that there are many vicious cycles, not only, cultivating
and maintaining an environment for cancer progression, but also transforming the
stroma as PCa progresses to aggressive disease (59). By interrogating pathways
integral to the tumor-stromal interactions at the metastatic sites, we may be able to
develop strategies that effectively disrupt the stroma-dependent tumor interaction. An
integral part of this thesis is to delineate factors expressed and secreted by the tumor
and stroma contributing to metastatic disease. As a result, we must first understand the
current molecular biology of PCa and factors that contribute to the initiation and
progression of PCa.
MOLECULAR BIOLOGY OF PROSTATE CANCER
Both genetic and epigenetic events have been shown to play a role in the
development and progression of PCa. Epigenetic changes, including methylation and
acetylation, represent some of the most common changes seen in early stage PCa. In
particular, DNA hypermethylation is a common event involving increased methylation
of DNA in multiple genes. The most hypermethylated genes contributing to PCa
initiation are glutathione S-transferase (GST) P1 gene, RASSF1A, RABB2, MDR1 and
APC. Of these hypermethylated genes, GSTP1 is cited heavily as being a major
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contributor to PCa initiation. GSTP1 is an enzyme catalyzing the addition of glutathione
to toxic compounds which in turn decreases cellular oxidative damage. Silencing and
promoter hypermethylation of GSTP1 is observed in 90% of PCa and these changes
may contribute to increases in cellular oxidative damage. Since GSTP1 expression is
decreased during the differentiation of basal cells to luminal cells, there may be a
predisposition to increased oxidative damage. Although important, these epigenetic
changes are only one event contributing to PCa initiation and progression. There are
also genetic changes, such as chromosomal losses, gains and rearrangements,
contributing to PCa progression. The loss and gain of chromosomal regions, specifically
regions of chromosomes 8, 10 and 21, represent some of the most frequently observed
changes in PCa progression and will be discussed in detail below.
One of the most frequently altered chromosomes is chromosome 8 with
frequent loss of 8p21 (79). Loss of the 8p21 region is an early and frequent event in
PCa, seen in 85% of carcinoma. One gene located in this region is the prostate-specific
homeobox transcription factor, Nkx3.1. Studies demonstrate that Nkx3.1 expression is
decreased in PCa, while deletion of Nkx3.1 results in PIN. This is supported by mouse
model studies demonstrating that Nkx3.1 -/- results in PIN lesions that do not progress
to PCa, but that cooperation of Nkx3.1oss and PTEN loss results in progression to PCa
and metastatic disease (80,81). As a result, loss of Nkx3.1 expression is alone
insufficient for progression to advanced PCa and involves other genetic events (82).
Another altered chromosome is chromosome 10 with frequent loss of 10q23.
One gene located in this region is the phosphatase and tensin tumor suppressor, PTEN,
which is also frequently lost in PCa (83). The loss of PTEN expression is mostly
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observed in advanced stage disease and accounts for >50% of PTEN gene alterations in
metastatic disease, while only a small fraction of primary tumors exhibit PTEN deletion
or mutation (84,85). This evidence is supported by genetically engineered mouse model
studies where PTEN inactivation in normal prostate epithelium drives the development
of advanced PCa (84).
Pten deletion studies demonstrate that PCa progression to metastatic disease is
a result of cooperation with multiple genes, such as simultaneous loss of Nkx3.1 and
Pten or inactivation of Pten and up-regulation of the proto-oncogene c-Myc (84,86-88).
These studies provide strong evidence that PTEN loss plays an important role in early
stage PCa and metastatic disease. There are also gains of chromosomal regions resulting
in changes that contribute to PCa progression.
One of the most frequently gained chromosomal regions is 8q24. One gene
frequently amplified in this region is c-Myc, a proto-oncogene known to regulate genes
involved in cell proliferation. It is overexpressed in ~40% of primary tumors and ~90%
of metastatic PCa (89,90). Mouse model studies report that prostate epithelium
overexpressing c-MYC develop PCa, but there is no observance of metastatic lesions
(91). More recent evidence suggests that progression to metastatic disease is thought to
require additional genetic alterations (92,93). These results demonstrate that changes to
chromosome 8, encompassing the Myc gene, play an important role in PCa, but Myc is
not a major contributor in the progression to metastatic disease. While chromosomal
losses and gains represent changes integral to PCa progression, chromosomal
rearrangements are a more recent area of interest in PCa progression.
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Chromosomal rearrangements were considered a rare event in PCa, but recent
evidence suggests that a specific chromosomal rearrangement at 21q plays an important
role in the progression of PCa. Studies demonstrate that the chromosomal
rearrangement of 21q, results in the fusion of the transmembrane protease serine 2 gene
(TMPRSS2) and the ETS gene, ERG, yielding a fusion protein found in the majority of
PCa (94,95). Specifically, the androgen-responsive TMPRSS2 promoter fuses with
select coding regions of the ERG family transcription factors, but other ETS-family
genes are also involved in recurrent fusions (96). The overexpression of the ETS family
of transcription factors accounts for ~60% of gene rearrangements in PCa and is
considered the most frequent event in human PCa (97). The rearrangement between
TMPRSS2 and ERG is the most frequent of all ETS-family genes. Although the
functional significance is not fully understood, in vitro and in vivo studies suggest that
activation of ETS genes enhances tumor-invasive properties (98,99). In addition,
mouse model studies demonstrate that ERG expression along with PTEN loss results in
HGPIN transition to PCa (99,100). These studies demonstrate that, although important
to PCa progression, these gene rearrangements are alone insufficient in driving
malignant disease.
The previous sections have discussed that epigenetic alterations and genetic
changes play a role in PCa progression. Signal transduction changes which may or may
not result from mutations comprise other changes that contribute to PCa progression. In
particular, the overexpression of kinases has been an area extensively studied and there
is more recent evidence implicating their role in PCa progression to metastatic disease.
Many kinases have been implicated in PCa progression, such as Her2/Neu, EGFR,
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PDGFR, FAK, Raf, VEGFR, PI3K/Akt, MAPK, Axl, MET and Src (101-106). In
particular, our laboratory has provided evidence that the oncogenic activity of Src plays
an integral role in PCa progression, especially, metastatic CRPC (107). The next
section will discuss the role of SFK activity in PCa and will provide information on
factors that may be associated with increased SFK activity in metastatic PCa.
THE ROLE OF SRC FAMILY KINASES IN PROSTATE CANCER
Of the nine family members, Src, Yes, Fyn, Lck, Lyn, Blk, Fgr, Yrk and Hck.
Of these nine members, Src, Yes and Fyn are the most ubiquitously expressed. In
normal tissues, SFKs act as key signal transduction molecules facilitating cellular
signals elicited by receptor protein tyrosine kinases, cytokine receptors, integrins, ion
channels and G-protein coupled receptors. Upon activation, SFKs regulate biological
processes, such as adhesion, migration, invasion, cell cycle and cytoskeletal changes.
These processes are regulated by mechanisms of SFK activity and involve changes in
the structural features of SFKs, which are outlined below.
Src Family Kinase: General Structure and Mechanism of Activation
Peyton Rous was the first to isolate the virus named Rous Sarcoma virus from
chickens. Years later, the identification of Rous Sarcoma virus as a type of retrovirus
that harbored transforming protein, v-Src, was recognized (108). These findings
contributed to the discovery, by Bishop and Varmus, of Src as the cellular form of v-Src
which was determined to be the product of the transforming gene harbored by avian
Rous Sarcoma Virus (109). A major finding regarding Src function demonstrated that
the Src protein possessed intrinsic protein tyrosine kinase activity making it the first
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identified gene product of this kind (110). Peyton Rous was awarded the Nobel Prize in
Medicine for his efforts in the discovery of the virus (111,112).
The structure of SFKs is composed of the following domains important to the
complete activation of the protein shown in Figure 2a and b. The Src homology
domain-4 (SH-4) is important for membrane localization by either palmitoylation or
myristoylation of which Src is the only member that does not undergo palmitoylation.
The SH-3 domain is a domain that recognizes prolines in the Pro-xx-Pro motif of other
substrates important for protein-protein interactions. The SH-2 domain recognizes
phosphorylated tyrosine residue-containing substrates and also serves to stimulate
protein-protein interactions. The SH1 domain serves as the catalytic kinase domain
comprising Y419 which is autophosphorylated upon Src activation. The C-terminal also
contains a negative regulatory phosphorylation residue at Y530. In the inactive state,
Y530 is phosphorylated forming an intramolecular interaction with the SH2 domain that
also associates with the SH3 domain and the linking region between the SH2 and kinase
domain. In particular, C-terminal kinase (Csk) and Csk homologous kinase are two
kinases that inactivate SFKs and the intramolecular interactions limit the accessibility of
substrates to be phosphorylated further maintaining an inactive Src state. In terms of
regulation of Src activation, there are several mechanisms outlined below.
One mechanism involves dephosphorylation of Y530 which increases the
dissociation of the C-terminal region from the SH2 domain resulting in an open
confirmation. Multiple phosphatases dephosphorylate the Y530, such as SH2-containing
phosphatase 1, protein tyrosine phosphatase (PTP)1B and PTP1α (112,113-115).
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Figure 2
Structure and Activation of Src Family Kinases
A. Structure of Src Family Kinase
Src family kinases consist of four domains and two regulatory regions that facilitate
intra and intermolecular interactions. These domains represent Src homology domains .
The regulatory regions are the negative regulatory (NR) domain and the unique region.
B. Regulation of Src activation
Src contains multiple domains serving different functions. SH4 domain contains a 15
amino acid sequence required for lipid modification along with a glycine needed for
myristoylation of Src. This site is critical for membrane localization. The unique
domain consists of multiple serine and threonine residues needed to facilitate
interactions with proteins, such as PKA, PKC and cdk2/cyclin. The SH3 domain
consists of the proline-rich (PXXP) motif needed for intra and intermolecular
interactions. The SH2 domain binds proteins containing phospho-tyrosine sites. The
SH1 domain is a highly conserved protein kinase domain containing Y419. This
domain facilitates autophosphorylation of Y419 upon Src phosphorylation. Lastly, the
negative regulator (NR) domain consists of Y530 which interacts with the SH2 domain
upon Csk (C-terminal Src kinase)-mediated phosphorylation.
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Other mechanisms involve deregulation of regulatory proteins, such as Csk, or
increased activity of cytoplasmic proteins. However, for full SFK activation,
autophosphorylation of Y419 must occur within the catalytic kinase domain. SFK
activation is also activated by cellular signals, such as RTKs, integrins and cytokine
receptors which modulate normal cellular functions, such as, survival, migration,
proliferation and invasion. SFK activation has been demonstrated to be aberrantly
active in multiple cancers, including PCa. However, studies have failed to provide
evidence of mutations as a mechanism for this aberrant SFK activation along with
previous studies suggesting that SFKs are not capable of cellular transformation. These
findings raised questions about how SFKs contribute to cancer progression. This has
prompted an increase in research investigating how SFK activity plays a role in cancer
progression.
Significance of SFK activity in cancer and PCa progression
Clinical studies report that SFK activity is increased in patients with advanced
disease correlating with shorter overall survival and increased metastatic incidence
(116-118). In vitro and in vivo studies supporting these reports come from our
laboratory and others demonstrating that SFK inhibition decreases tumor growth and
metastatic potential in multiple cancers, including PCa (107,119-123). A pinnacle
study, providing strong evidence that Src promotes tumor progression, by Agarwal et al.
demonstrated that increased Src activity is an independent prognostic indicator at
multiple stages of colon carcinoma (124). This provided foundational evidence
suggesting that Src, of the many SFKs, may play a role in many stages of mulitple
cancers, including PCa.

~ 19 ~

Earlier reports demonstrate that Src is important in the development of PCa
and progression (125-129). In contrast to earlier reports, recent evidence suggests that
Src, along with Fyn and Lyn, result in transformation of prostate epithelium suggesting
a more functional role in the early events of PCa progression (37). This study further
reports that among Src, Lyn and Fyn, Src demonstrates the strongest transforming
capacity and oncogenic phenotype. As a result, increased Src activity has been
implicated as a central signaling component of PCa progression that contributes to
changes in multiple stages of PCa progression. One thought regarding Src’s increased
activity is that Src’s activity has also been demonstrated to be regulated by upstream
signaling mechanisms which may contribute to changes in PCa progression. Upstream
signaling is thought to be one mechanism by which Src activity is increased in cancer
and, as such, the investigation of signaling mechanisms mediating Src activity in PCa
has been of interest. Rather than provide all of the signaling mechanisms involved, this
thesis aims to focus on signaling families that mediate Src activity in PCa progression,
which will be discussed in the next section.
Significance of Src signaling mechanisms in PCa
Multiple studies demonstrate that Src activation can occur through activation
of integrins, RTKs and cytokine receptors in many cancers show in Figure 3 (130-132).
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Figure 3
Src-Mediated Pathways in Cancer
This figure displays pathways that Src regulates in multiple cancers. Src regulates
pathways that modulate survival, angiogenesis, proliferation and motility/migration
events.
Summy JM and Gallick GE. Clin Cancer Res 2006 Mar 1; 12(5): 1398-401
Reproduced with permission
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In PCa, our laboratory reports that integrin clustering regulates the recruitment of Src to
activated FAK stimulating the activation of related signaling pathways, such as PI3K,
Rho, Ras, paxillin, p130Cas, ERK and MAPK leading to changes in motility/migration,
invasion and cell spreading (131). In addition, there are multiple RTKs with intrinsic
protein kinase activity that have been demonstrated to modulate Src activation in PCa,
outlined in multiple reports (103,133-136). Our laboratory offers additional reports
demonstrating that tyrosine kinases, receptor and non-receptor, contribute to metastatic
properties of PCa cells (107, 137,138). This work has provided a great deal of evidence
showing that signaling through integrins, RTKs and other tyrosine kinases, not only
regulates Src activation, but facilitates changes in metastatic properties of PCa. More
recently, another upstream signaling mechanism has received more attention for its role
in tumor progression, GPCRs, but whether it modulates Src activation and facilitates
changes to metastatic properties of PCa progression is unclear and is the focus of this
thesis.
GPCRs are considered to be the largest family of cell surface molecules
facilitating signal transduction pathways regulating biological functions through stimuli,
including peptide growth factors, hormones and cytokines. Studies demonstrate that the
expression of GPCRs and GPCR ligands are increased in multiple cancer cell lines and
tumors, including PCa (138-141). This has been outlined in a comprehensive review of
the role of GPCRs in cancer by Dorsam and Gutkind (142). There is emerging
evidence demonstrating that GPCRs and GPCR ligands, such as interleukins, initiate
intracellular signaling cascades involving many factors, including protein kinases and
cytokines, regulating many metastatic properties of PCa (143-145). This information,
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provided in the next section, is minimal and limited in scope, but provides foundational
support for the role of GPCR ligands and GPCRs in PCa progression.
There is evidence demonstrating that Src-mediated changes may be influenced
by GPCR ligands, such as IL-8, in PCa, the focus of this thesis (146,147). One study,
from our laboratory, demonstrates that Src inhibition decreases interleukin 8 (IL-8)
cytokine production in PCa cells suggesting that Src-mediation of PCa progression may
be regulated by, not only integrins and RTKs, but also by GPCRs and/or GPCR ligand
upstream signaling (148-149). However, there is limited information about what
GPCR-initiated signaling cascades are involved in regulating Src activation and what
metastatic properties it modulates in PCa. As a result, it is of interest to this thesis to
identify GPCR-regulated mechanisms that facilitate Src-mediated changes in metastatic
properties of PCa. However, signaling mechanisms facilitating Src activation in PCa
provide only one possibility of how Src regulates PCa progression. There may also be
Src signaling mechanisms present in the tumor microenvironment which contribute to
PCa progression, an emerging field of study and another focus of this thesis. The
following section will discuss Src’s role in the tumor microenvironment.
Significance of Src in the tumor-stromal microenvironment
The role of Src in the tumor microenvironment has been mostly observed in
bone metastases and in osteoclast and osteoblast functions. Initial studies demonstrate
that Src -/- mice undergo osteopetrosis, a bone-remodeling disorder, causing defective
bone resorption by osteoclasts (150). This study led to multiple studies dedicated to
Src’s role in bone based upon the fact that Src inhibition may decrease bone turnover.
Studies supporting this theory demonstrate that inhibition of Src increases osteoblast
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differentiation and bone formation while decreasing osteoblast proliferation. Src also
regulates the bone remodeling process by negative regulation of osteoblasts and positive
regulation of osteoclasts (151). The use of Src inhibitors in in vitro studies, such as
dasatanib and saracatanib, demonstrated decreases in bone regulatory mechanisms, such
as osteoclast activity and PCa-cell induced osteoclast activity (152-154). As projected
by the initial src -/- mouse study and the ensuing in vitro studies, multiple Phase I and II
clinical trials have been conducted with SFK inhibitors demonstrating decreases of bone
remodeling markers, such as N-telopeptie of type 1 collagen (urinary NTX) and Ctelopeptide of type 1 collagen (serum CTX) in healthy men. This led to Phase I/II trials
with saracatinib and dasatanib which showed promising results, in the dasatanib trial, in
a small cohort of men with metastatic CRPC.
Although these studies suggest that Src modulates biological functions of the
tumor and possibly the bone microenvironment, there are still some patients that will
not respond to these therapeutic strategies. As a result, we must investigate other cell
types in the tumor microenvironment contributing to tumor progression that contain
Src-mediated signaling cascades. Earlier reports show that increased Src expression in
bone marrow stromal cultures correlates with increased growth factor and cytokine
stimulation (155). Another study demonstrates that Src activity mediates prostate
epithelial cell migration to prostate stromal cells in the presence of growth factors (156).
These studies suggest that Src regulates signaling pathways in cells supporting and
associated with PCa progression, but the mechanism of Src activation and signaling
pathways associated with Src activation in the stromal microenvironment are unclear.
However, there is information to suggest that, not only Src activation, but factors
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produced and secreted by the stromal microenvironment contribute to PCa progression.
Recent studies suggest that one of those stromal produced factors, IL-8, modulates
tyrosine kinase activation, but it is unclear if or how tumor and stromal produced IL-8
modulates the tyrosine kinase activation of Src to promote the metastatic potential of
PCa. As a result, an integral part of my PhD thesis will be to determine how IL-8
contributes to Src activation in metastatic properties of PCa as well as explore how
stromal produced IL-8 contributes to Src activation in PCa. The next section will
introduce and discuss the function and roles of IL-8 in PCa.
THE ROLE OF INTERLEUKIN-8 IN PROSTATE CANCER
Of the many cytokines and chemokines discovered, IL-8 represents one that
modulates a variety of biological processes, not observed, by other cytokines. Much of
the work addressing the roles of cytokines in PCa has been focused on IL-8, IL-12 and
IL-6. IL-6 has been associated with tumor burden and metastatic CRPC, but in vitro
studies have identified IL-6 more as a facilitator of growth and survival while IL-12 has
been shown to modulate, primarily, invasion of PCa cells in vitro (158-161). It is
evident that these cytokines play important roles in modulating biological functions of
PCa progression, but it is unclear what role IL-8 signaling plays in PCa progression to
metastatic disease and the mechanism of IL-8 signaling in biological functions of PCa.
This thesis will discuss these topics in upcoming sections. The following section will,
first, discuss IL-8 structure and regulation.
Interleukin 8: General Structure and Regulation
IL-8 (also known as CXCL8, GCP-1 and NAP-1) is an 8 kDa member of the
CXC chemokine family. The IL-8 protein belongs to a family of CXC chemokines
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denoted by two cysteines surrounding any amino acid. IL-8 is also classified according
to the absence or presence of the ELR (Glu-Leu-Arg) motif in the N-terminus. IL-8 is a
99-amino acid precursor which is processed as a mature protein by cleavage of the
leader sequence. Two forms of the mature protein exist, a 72-amino acid protein and a
77-amino acid protein with the 72-amino acid protein representing the most
predominate form. (Figure 4a and b) It was first discovered as a pro-inflammatory
cytokine on chromosome 4 secreted by human blood monocytes and later redefined as a
“chemokine” for its chemotactic capabilities.
Since then, IL-8 has been shown to be expressed and secreted by multiple cell types
including stromal cells and tumor cells (162). Binding studies indicate that IL-8 binds
to two G protein coupled receptors, CXCR1 and CXCR2. CXCR1 exhibits high
affinity for IL-8 while CXCR2 exhibits affinity for three ligands, IL-8, GROα and
NAP-2 (163,164). Although the role of CXCR1 and 2 are important to the function of
IL-8, there is still controversy over how the receptors contribute to biological functions
and how they initiate changes in cancer progression which will not be a highlight of this
thesis. This thesis will address the importance of IL-8 in cancer progression with an
emphasis on its significance to PCa progression outlined in the next section.
Significance of IL-8 in cancer progression
Clinical evidence demonstrates that increased IL-8 expression and serum levels
correlates with poor prognosis and recurrent disease in many cancers, including
melanoma, ovarian, colon, lung, breast, lymphoma, head and neck small cell carcinoma,
liver and prostate (165-171). Therapies targeting IL-8 have been investigated, such as
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Figure 4
Structure and Regulation of Interleukin 8
A.
Illustration of IL-8 and sites required for activity. The ELR sequence is
essential to the binding of the IL-8 receptors and for its activity . The tyrosine and
lysine residues and the alpha helical region located near the C-terminus are required for
binding of the IL-8 receptors as well.
B.
Transcriptional regulation of IL-8. The picture shows transcription factors
important in IL-8 transcription. The basal levels of transcription are regulated by
binding of the NF-kB repressing factor (NFR) to the negative regulatory element
obstructing NFk-B binding. Binding of octamer-1 (OCT-1) occupies the C/EBP site
and deacetylation of histone proteins by histone deacetylase 1 (HDAC-1) modulates
basal transcription as well. Upon either induced or constitutive activity, NFk-B
translocates to the nucleus binding near NRF. C/EBP occupies the OCT-1 site while
CREB binding protein (CBP)/p300 initiates chromatin remodeling through histone
acetylation and activator protein-1 (AP-1) transcription factor becomes phosphorylated
as well. The culmination of these events results in transcription of IL-8.
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the administration of the humanized monoclonal antibody ABX-IL-8. ABX-IL-8
administration demonstrated decreased metastatic potential of melanoma in xenograft
models and decreased tumor growth in bladder cancer (172-173). Although this
treatment did not provide significant clinical benefit, it provided necessary information
regarding how IL-8 signaling modulates tumor progression in a subset of cancers.
Many of these studies prompted the investigation of a potential role for IL-8 in PCa
progression.
Significance of IL-8 in PCa progression
Zabransky et al. demonstrate that lenalidomide treatments decreased IL-8
serum levels in patients with PCa, but, interestingly, IL-8 levels remained high in
patients who progressed (169). A phase I/II trial with Dasatanib demonstrates that a
cohort of responding patients display a decrease in serum IL-8 while non-responders
showed either increased or stable IL-8 levels. Dayanni et al. report a correlation
between dasatanib levels and decreased serum IL-8. This preliminary data strongly
suggests that IL-8 may be an additional marker of response, but a larger study is
warranted and has been completed with results pending. Further support comes from in
vitro and in vivo studies demonstrating that IL-8 expression correlates with
tumorigenecity and metastasis of PCa (172,173). However, there is controversy and
unclear evidence concerning IL-8’s particular role in metastatic CRPC.
In vitro studies have demonstrated that IL-8 overexpression in androgenpositive cells desensitizes PCa cells to anti-androgens, such as bicalutamide and the
DNA damage agent, oxaliplatin, while IL-8 also reduces growth inhibition
(146,174,175). In contrast, another report demonstrates IL-8 increases the proliferation
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of PCa cells, but this is not observed in the presence of bicalutamide (176). Other
conflicting results from these and other studies are surrounded around how IL-8
regulates AR and PSA levels (146,147,176). These controversies have also led to an
unclear understanding of how IL-8 signaling modulates PCa progression and the
metastatic properties it involves. This thesis will identify IL-8 signaling pathways
involved in regulating metastatic properties of PCa progression to metastatic CRPC.
The next section will discuss studies prompting more investigation about the signaling
mechanisms and biological processes surrounding the role of IL-8 in PCa progression.
Significance of IL-8 in metastatic properties of PCa
IL-8 induces classical biological functions including, chemotaxis, migration,
calcium mobilization, protein translation, inflammatory responses and cell proliferation,
with chemotaxis and migration being the first identified biological effects in normal
cells, illustrated in Figure 5. IL-8 was recognized as a regulator of chemotaxis through
neutrophil-activation in vitro (163). Later studies demonstrated that IL-8 is involved in
other biological functions of normal cellular functions and cancer cell functions. One of
the first studies observing IL-8 in PCa demonstrated that neutralization of IL-8
decreases angiogenic activity and tumorigenecity of PC-3 cells (249). Since then, it has
been well established that IL-8 plays a critical role in angiogenesis of cancer cells
(177,178). Kim et al. demonstrated that PCa cell lines express high levels of IL-8
contributing to increases in microvessel density increasing prostate tumor growth (179).
In vivo studies by Inoue et al. also report increased VEGF and IL-8 expression
demonstrating a correlation between neovascularization and IL-8 expression (173).
More recent studies have been aimed at determining factors that potentially regulate IL-
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8 or that IL-8 regulates modulating angiogenesis (146,147,175,176). There have been
many advances made in understanding the role of IL-8 in the process of angiogenesis in
PCa, but there has been and increasing effort put towards understanding how IL-8
contributes to other biological processes of PCa, such as migration and invasion and its
suggested role in the progression to metastatic PCa.
Although the first studies demonstrate IL-8 as a novel chemoattractant,
subsequent reports determined that IL-8 also regulates shape change and directional
migration (180-182). As a result of these studies, IL-8 has been identified as a migratory
regulator in multiple cancers, acute myeloid and lymphoid leukemia (AML and ALL)
and melanoma being the first cancers to describe IL-8 as a relevant chemoattractant and
migratory factor (183,184). Bar-Eli et al. demonstrates that IL-8 directly regulates
matrix metalloproteinase (MMP) gene expression increasing invasion providing some
of the foundational studies for examining the invasive role of IL-8 in numerous cancers,
including PCa (185). Following these studies, Reiland et al. provided one of the first
PCa studies demonstrating that PCa cells show significant increases in migration and
invasion in response to exogenous IL-8 (186). Inoue et al. also demonstrates that
overexpression of IL-8 in PCa cells significantly increases migration, while antisense
transfection of IL-8 in high IL-8 expressing PCa cells decreases
migration (173). More recent studies have demonstrated that IL-8 increases the
migration of androgen-independent PCa cells suggesting that IL-8 production regulates
PCa progression in the absence or in the place of androgen regulation (146,147). This
evidence suggests that IL-8-mediated migration and invasion participates in PCa
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progression to a metastatic phenotype, but there are questions about the signaling
mechanisms involved.
Significance of IL-8 signaling in metastatic properties of PCa
Although information regarding IL-8 signaling cascades modulating biological
functions of PCa is increasing, the mechanisms are still unclear. A comprehensive
review by Waugh et al. provides a schematic of suggestive IL-8 signaling pathways that
contribute to biological functions of cancer progression (175). There is information
regarding specific canonical IL-8 signaling pathways regulating biological functions of
cancer and it is suggested that protein tyrosine kinase activity is involved, where the
clinical observation of increased IL-8 expression and SFK activity in PCa tissues, these
reports provide interesting implications for a cooperative role of IL-8 and Src in PCa
progression. This phenomenon had not been explored until recently where the results
are interesting, but inconclusive, and are limited in scope.

In PCa, studies suggest that IL-8 signals through tyrosine kinases, such as Src
and FAK, during the transition of androgen dependent PCa to androgen independent
PCa (146,147). A recent study demonstrates that IL-8 participates in the transition of
androgen dependent PCa to androgen independent PCa by increasing AR transcriptional
activity (176). These reports suggest that, not only, do tyrosine kinases activate
signaling mechanisms important for metastatic properties in PCa cells, but that this may
occur through IL-8 cytokine-induced stimulation of tyrosine kinase activity in
metastatic CRPC (146,147). As a result, this thesis will address if IL-8 and Src
cooperate to induce changes in biological functions related to PCa progression to
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Figure 5
IL-8-Mediated Signaling Pathways in Cancer
This is a simplified illustration of how IL-8 regulates multiple pathways that lead to
changes in angiogenesis, proliferation, invasion and survival. The solid blue lines are
known pathways that IL-8 regulates, such as the canonical IL-8 activation of PLC and
PKC. The dashed blue lines represent less understood pathways of IL-8 regulation,
such as the IL-8-mediated regulation of RhoGTPase. Lastly, the orange solid lines
represent pathways that stimulate transcription factor activity. This illustration displays
known and unknown pathways of IL-8 regulation and modulation of multiple biologic
functions of cancer.
DJ Waugh Clin Can Res 2008 Nov 1;14(21): 6735-41
Modified with permission
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metastatic disease. In addition to understanding the contributions of factors expressed
and secreted by the tumor and their role in tumor progression, PCa is also influenced by
the microenvironment. As a result a major thrust of this thesis will be to address how
IL-8 signaling in the tumor microenvironment affects PCa progression. The next
section will discuss the importance of understanding IL-8 in the tumor
microenvironment and what role that plays in PCa progression.
Significance of IL-8 in the tumor-stromal microenvironment
It is well established that IL-8 is a potent cytokine secreted by cell types
surrounding and interacting with cancer cells. The intratumoral production of IL-8 is
associated with increased survival and growth, but IL-8 production also occurs by cells
supporting the tumor. Initial studies demonstrate that IL-8 is expressed and secreted in
abundance by bone marrow stromal cells (190,191). Other studies demonstrate that IL8 is elevated in bone remodeling cells and fibroblastic stromal cells, two cell types
directly interacting with PCa cells. Earlier studies supporting this demonstrate that the
stromal compartment has a direct impact on epithelial cell behavior (192). However,
initial studies reported the stromal compartment as a passive structure of support with
very little aid to the biological function of cells. Over the past decade, there has been
increasing evidence demonstrating that the stromal compartment provides a permissive
and supportive environment of survival for cancer cells. As a result, it is suggestive that
cancer progression, including PCa, is also a result of microenvironmental-mediated
effects.
These microenvironmental-mediated effects have been studied in other cancers
and have demonstrated that cancer-produced growth factors and cytokines modulate
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bone formation (193,194). Interestingly, evidence also demonstrates that IL-8 can
induce fibroblast or stromal derived cells to become reactive stroma. (196). As the
information grows concerning how factors, such as IL-8, modulate the
microenvironment, there is less information indicating the sources of IL-8 production,
albeit tumor-produced and/or stroma-produced. There is also little evidence discussing
how this IL-8 production affects PCa progression and what IL-8 signaling pathways are
involved.
It is possible that a heterotypic crosstalk mechanism exists whereby IL-8
production by either the stromal or tumor compartments modulates IL-8-mediated
signaling pathways in the tumor compartment to increase PCa progression. Since, there
is evidence supporting a collaborative role of IL-8 and Src in PCa progression, there is a
possibility that the crosstalk mechanism in the stromal compartment involves these
factors. However, this has not been studied and will be addressed in this thesis.
We know that the tumor microenvironment provides a rich milieu of factors
contributing to PCa cell survival, proliferation, migration and invasion. IL-8 production
by fibroblasts and stromal cells is associated with survival of PCa cells, but we do not
know if Src is involved in this mechanism and whether this is an IL-8 autocrine and/or
paracrine mediated event. There have been preclinical mouse model studies addressing
the role of IL-8 in the metastatic potential of PCa (173,196). These studies suggest that
overexpression of IL-8 increases the metastatic potential of PCa in mouse models, but
the microenvironment-mediated nature of PCa leads us to hypothesize that the tumor is
not the only contributing cell type in PCa progression to metastatic disease.
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Questions that are still unclear are how and why the tumor-stromal interaction
affects the metastatic potential of PCa, which is integral to this thesis. These questions
are capitalized by current efforts to assess therapeutic strategies that target factors
expressed and/or secreted by both tumors and microenvironmental cells. The next
section will discuss current therapeutic strategies in PCa and will highlight the efforts
made in developing strategies that target the tumor and microenvironment.
CURRENT STRATEGIES IN TREATING PROSTATE CANCER
Treatment strategies for localized and castration resistant prostate cancer
Treatment of localized PCa usually involves radiation or surgery which
eradicates nearly 100% of the cancer, but there are 30-50% of these patients that will
incur either a local or distant recurrence. For recurring patients, first-line therapies
involve androgen deprivation therapies (ADT), such as luteinizing hormone-releasing
hormone (LHRH) and anti-androgens, but unfortunately in many of these patients,
CRPC develops. Many of the earlier treatment options for CRPC, such as
mitoxantrone-based treatments or bisphosphonates, provided palliative benefits, but did
not provide overall survival benefits (197,198). In 2004, the randomized clinical trials,
TAX 327 and SWOG 9916, reported the first evidence for increased survival benefit
and reduced PSA in patients with metastatic CRPC using docetaxel-based
chemotherapies and resulted in FDA approval for use of docetaxel as a treatment for
metastatic CRPC (199,200). Docetaxel was the only FDA approved drug used to target
metastatic CRPC. Now, multiple drugs have been approved due to the increased
number of drugs entering into clinical development. The number of drugs in clinical
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development has increased, in part, due to the advances in the understanding of the
cellular and biological mechanisms of PCa progression.
The principal increase in understanding that has led to new drugs is that
androgen ablation does not effectively block AR signaling. As a result, there has been
increased development of anti-hormonal therapies, such as abiraterone acetate and
MDV3100. Abiraterone acetate, an inhibitor of the key enzyme for hormonal synthesis
(cytochrome P17), demonstrated a >50% decline in PSA in CRPC docetaxel-treated
patients in a phase II trial with 38% of the patients showing partial response and also
demonstrated an overall survival of ~4 months with abiraterone treatment. In April
2011, abiraterone became an FDA-approved anti-androgen therapy for use in metastatic
CRPC (5,201). MDV3100, an AR antagonist, has also been used in a phase I/II study
whereby patients treated with chemotherapy showed >50% decrease in PSA and nonchemotherapy treated patients displayed >60% decrease in PSA levels (202).
MDV3100 (Enzalutimide) is now an FDA approved therapeutic agent that disrupts
translocation of AR to the nucleus decreasing AR binding to DNA and preventing
coactivator recruitment which is a proposed mechanism thought to contribute to tumor
regression of CRPC (202). These results suggest that patients with androgen responsive
metastatic CRPC may gain from therapeutics targeting continued AR signaling.
However, targeting sustained androgen signaling is only one aspect of current
therapeutic strategies addressing the cellular events in metastatic CRPC. Therapies
targeted against signaling molecules, such as growth factor and tyrosine kinase
signaling, upregulated in metastatic CRPC are needed as well.
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The observed aberrant expression of kinase pathways, such as Her2/Neu,
EGFR, PDGFR, FAK, Raf, VEGFR, PI3K/Akt, MAPK, Axl, MET and Src, in
metastatic CRPC have prompted the development of many therapeutic agents (203206). Detailed information regarding these pathways will not be discussed further, but
are mentioned to highlight that targeting aberrantly active kinase pathways is an
increased area for therapeutic strategy. However, I will discuss recent efforts in the
development of therapeutic strategies for targeting the aberrant activity of the tyrosine
kinase, Src, a major subject of this thesis. These recent efforts are, in part, due to
studies from our laboratory and others demonstrating aberrant Src activity in the
progression of PCa to metastatic CRPC and in the microenvironmental compartment as
well.
Evidence suggests that the expression of Src in multiple microenvironment cell
types contributes to the progression of PCa. Mouse model studies using Src -/- mice
develop osteopetrosis (bone-building disease) suggesting that Src expression impairs
osteoclast activity important for the balance of the bone remodeling process (207). The
disruption of Src activity also increases bone-building activities by negative regulation
of osteoblasts (151). Araujo et al. provides a comprehensive review demonstrating that
SFK inhibition has anti-osteoclast activity preventing osteolytic metastases in breast
cancer and decreased growth of tibially-injected prostate tumors (208). These studies
have prompted the development of SFK inhibitors, such as AZD0530 (Saracatinib) and
Dasatanib, that demonstrate inhibition of tumor growth and osteoclast activity.
Saracatinib was introduced as a dual SFK/Abl inhibitor and has demonstrated promising
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in vitro and in vivo results and has entered into phase I/II trials (209,210). The clinical
importance of SFK inhibition by Saracatinib is still pending.
Dasatanib is another SFK inhibitor that is considered to be the most clinically
studied Src inhibitor (212). Dasatanib was developed as a potent biochemical inhibitor
of Src and Bcr/Abl kinase activity in multiple solid tumors, including PCa. Initial in
vitro findings demonstrated that dasatanib, now known to be a multi-kinase inhibitor,
decreases SFK activity in PCa cell lines (107,117). Preclinical studies from our
laboratory demonstrate that dasatanib decreased lymph node metastases as well as
migration and invasion of cells in vitro (107). In 2009, our institution completed a
Phase 1/2 trial on dasatinib + docetaxel, with results so promising a worldwide Phase 3
trial has been completed with results pending (211). Some of the preliminary results
demonstrate that combination therapy of docetaxel and dasatanib in metastatic CRPC
(CA180-086) showed dramatic decreases in bone alkaline phosphatase, BAP, and
urinary N-telopeptide, UNTx and 28% of patients displayed a reduction in size and
number of lesions due to bone scan (213). The remaining endpoints of overall survival
and progression free-survival are being analyzed. These studies suggest that dasatanib
may serve therapeutic benefit for patients by targeting, not only, metastatic CRPC, but
also the tumor microenvironment. As mentioned, osteoblast and osteoclasts are two cell
types in the tumor microenvironment affected by Src, but cytokine-producing cell types,
such as fibroblasts are also located in the tumor microenvironment. One of the
cytokines produced by fibroblasts is IL-8 known to be important in PCa progression.
We are slowly gaining an understanding of the biological pathways and
mechanisms over-expressed or deregulated in metastatic CRPC. The combination of
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therapies targeting kinase-mediated signaling pathways in the tumor and the
microenvironment may serve as one therapeutic strategy to disrupt the growth and
progression of metastatic CRPC. As a result, this thesis will focus on understanding
thecontributions of Src signaling in metastatic disease and will identify signaling
pathways associated with progression to metastatic disease.

SUMMARY OF PROBLEM AND HYPOTHESIS
Prostate cancer is a leading cause of cancer mortality in men in western
civilization. While localized disease is almost always incurable, <40% of men will
incur metastatic disease despite local therapies. As a result, therapies targeting factors
involved in PCa progression will be beneficial in preventing metastatic spread. Two
contributing factors to the metastatic spread of PCa are IL-8 and Src. These factors are
also produced and expressed by microenvironmental cells, such as stromal cells, which
take part in the bidirectional interactions increasing prostate carcinogenesis.
The goal of this Ph.D. dissertation is to investigate the role of IL-8-mediated Src
family kinase activation in tumor-tumor and tumor-stromal interactions in metastasis of
prostate cancer. Previous studies suggest that aberrant Src activity regulates functions
that increase IL-8 secretion by PCa cells. In addition, IL-8 overexpression, by the
tumor and stroma, and increased Src activity have, individually, been implicated as
mediators of PCa progression. However, there is not a clear understanding of the
relationship between IL-8 signaling and SFK activation. The questions surrounding IL8 and SFK involvement in PCa are: 1) is there a feed forward loop whereby IL-8induces Src activation further increasing IL-8 secretion which affects metastatic
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properties of PCa? 2) is there a paracrine mechanism whereby IL-8 production by the
stroma affects Src activation and metastatic properties of PCa? and 3) how does IL-8
production by the stroma affect tumor growth and metastatic potential?
The hypothesis tested in the work of this dissertation is that IL-8-mediated Src
activation regulates increased metastatic potential of prostate cancer through tumortumor and tumor-stromal interactions. To test this hypothesis, I determined if IL-8
expression and secretion by PCa cells affects Src activity and migration in vitro. I next
determined the effects of stroma-produced IL-8 on migration and invasion of PCa
through Src activation in vitro. Lastly, I determined whether IL-8 production by the
stroma affects tumor growth and metastatic potential in vivo. The work in this
dissertation has led to a better understanding of how IL-8 signaling in PCa and the
stroma modulates PCa progression as well as increased our understanding of the role of
SFK activation in IL-8 signaling in PCa.
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CHAPTER 2
MATERIALS AND METHODS

~ 41 ~

Cell Lines
The approach for this study was to use two well established cell culture models
that mimic the progression of PCa from low metastatic to high metastatic potential with
high metastatic potential representing advanced stage disease. The LNCaP human PCa
progression model and the PC3 model contain isogenic variants of differing metastatic
potential. The LNCaP cells are non-metastatic and androgen dependent while C4-2B4
cells are bone metastatic and androgen independent, as previously described (43). The
LNCaP cell lines were provided by Dr. Mike Gray (MDACC). The PC3-MM2 cell line
was created and kindly provided by the lab of Dr. Isaiah J. Fidler in the Department of
Cancer Biology, the University of Texas MD Anderson Cancer Center. PC3 cells are
low metastatic and androgen-dependent while PC3-MM2 cells are lymph node
metastatic and androgen-independent, as previously described (214,215). The HS5 cell
line is an immortalized fibroblastic stromal cell derived from human bone marrow and
purchased from ATCC. This cell line was established as previously described (224).
Briefly, the LNCaP and C4-2B4 cell lines were maintained in RPMI 1640
medium (Sigma Aldrich) containing L-glutamine supplemented with 10% fetal bovine
serum (FBS), 1% penicillin/streptomycin (HyClone), MEM Non-Essential Amino
Acids (NEAA), Sodium Pyruvate and MEM Vitamin Solution. NEAA, Sodium
Pyruvate and Vitamin Solution were purchased from Gibco. The PC3, PC3-MM2 and
HS5 cell lines were maintained in Dulbecco’s Modified Eagle Media (DMEM)/ Ham’s
F-12 (Sigma Aldrich) medium supplemented with 10% FBS and 1%
penicillin/streptomycin. Cells were also tested for mycoplasma using an enzymatic
based method, MycoAlert™ Detection Kit, by Lonza and polymerase chain reaction

~ 42 ~

(PCR) method, Lookout® Plasma Elimination Kit by Sigma Aldrich. All cells were
tested and found to be mycoplasma free.
Reagents
Recombinant IL-8 (72a.a.;rh-IL-8) was purchased from PeproTech. The
thiazole-based dual Src/Abl kinase inhibitor, 2-acylamino-5-carboxamidothiazole
(BMS-354825/dasatanib) was a gift from Bristol Myers Squibb.
Construction of Lentiviral shRNA to IL-8
For this study, PC3-MM2 and HS5 cells were infected with a GFP-labeled
lentiviral-based IL-8 short hairpin RNA (shRNA). The lentiviral system is a wellestablished system developed by Didier Trono and the specific lentivirus system for IL8 was made and kindly provided to us by Dr. Bar-Eli (215). Briefly, sense and
antisense oligonucleotides from the IL-8 siRNA target sequence (5’-GCCAAGGA
GUGCUAAAGAA-3′) were designed with a hairpin and sticky ends (ClaI and MluI),
annealed to the green-fluorescent protein (GFP) labeled pLVTHM lentviral gene
transfer vector, used for DNA isolation and lentiviral production by the described
method (216). A nontargeting sequence (5′-UUCUCCGAACGUGUCACGU-3′) was
used as a control.
After plating of PC3-MM2 or HS5 cells, 500ul of viral supernatants were
added to semi-confluent cells along with 6ug/ml of polybrene infection reagent
(Millipore) and 500ul of growth media. After 48 hour incubation, GFP cells were
visualized using fluorescence microscopy. Cells were then expanded to 150cm2 tissue
culture plates and GFP sorted by fluorescence activated cell sorting (FACS) using the
Flow Cytometry and Cellular Imaging (FCCI) Core Facility at MD Anderson. qRT-
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PCR and ELISA was performed to determine if endogenous and secretory IL-8
knockdown using methods in the previous mentioned sections on qRT-PCR and ELISA.
Construction of IL-8 expression vector
The work discussed in this section was done in collaboration with Lily Huang
and Dr. Bar-Eli (Department of Cancer Biology, MDACC). The protein encoding
region was amplified from human PC3-MM2 cDNA using the Touchdown PCR
program. This method is useful in increasing the annealing specificity of PCR by using
multiple cycles and multiple annealing temperatures enhancing formation of a more
specific final PCR product. The sequences for the PCR primers were made with
restriction enzyme sequences for Xho1 and Sal1 (Promega) - F- 5’ GGCTCGAG
GCCACCATGACTTCCAAGCTGGCCGT-3’ and R- 5’ GAGTCGACTTATGAA
TTCTCAGCCCTCT-3’. The program was as follows: 94°C for 2 min.; 10 cycles of
94°C for 15 sec., 68°C for 45 sec., -1.5 sec/cycle, 72°C for 2 min 30 sec.; 35 cycles of
94°C for 15 sec., 50°C for 45 sec., 72°C for 2 min 30 sec, + 3 sec/cycle; 72°C for 20
min. and holding at 4°C. PCR samples were purified using QIAquick PCR Purification
Kit (Qiagen). Digestions were completed with purified PCR and pSI vector (Promega)
according to manufacturer’s protocol (Promega). Digested vector and PCR were run on
a crystal violet gel. Bands specific to IL-8 and digested pSI vector were extracted from
the crystal violet gel using the gel extraction method and purified using the EZ Gel
Extraction Kit (EZ Bioresearch) and Geneclean Turbo Kit (QBiogene) following the
manufacturer’s protocol. The pSI vector and IL-8 purified DNA were ligated and
transformations were performed using XL-10 Gold competent cells using the
manufacturer’s protocol (Stratagene). After selection of 8-10 single colonies and
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expansion, DNA was purified by performing the QIAPrep Spin Miniprep Kit according
the manufacturer’s protocol (Qiagen). Completion of cloning was observed by enzyme
digestion and pSI/IL-8 DNA samples were confirmed by DNA sequencing using the
DNA Analysis Core Facility (DAF) at MD Anderson Cancer Center.
Construction of IL-8 mutagenesis vector
We constructed a sequence that introduced point mutations in the shRNA
target region without affecting the peptide sequences. The QuikChange II XL Site
Directed Mutagenesis (Stratagene) method allowed us to make point mutations in the
basic IL-8 expression vector through PCR-based methodology. Mutagenic primers
were designed using the QuikChange Primer Design Program
www.agilent.com/genomics/qcpd. The primers are as follows: F-5’
CTGTGTGAAGGTGCAGTTTTACCTAGAAGCGCAAAGGAGCTTAGATGTCAG
TGCATAAAG-3’andR-5’ CTTTATGCACTGACATCTAAGCTCCTTTGCGCTTCT
AGGTAAAACTGCACCTTCACACAG-3’.
Briefly, synonymous mutations were introduced into the pSI/IL-8 DNA by
performing PCR using PfuUltra Hotstart DNA polymerase. After Dpn1 digestion of
amplified product, transformation into XL-10 Gold ultracompetent cells (Stratagene)
was performed according to manufacturer’s protocol. After selection of 8-10 single
colonies and expansion, DNA was purified by performing the QIAPrep Spin Miniprep
Kit according the manufacturer’s protocol (Qiagen). Completion of cloning was
observed by enzyme digestion and pSI/IL-8 DNA samples were confirmed by DNA
sequencing using the DNA Analysis Core Facility (DAF) at MD Anderson Cancer
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Center. pUC18 transformation and pWhitescript mutagenesis controls provided with
the kit were used.
The resulting rescue vector, pSI/IL-8, was transfected into cells using Fugene 6
(Roche) according to manufacturer’s protocol and Quantikine IL-8 ELISA (R&D
Systems) was performed to determine IL-8 levels.
Immunoblot
Cell lysates were extracted using previously described methods (107). Protein
concentration was determined by RC DC BioRad Protein Assay Kit followed by
spectrophotometric analysis by the Perkin Elmer Envision 2104 Multilabel Reader.
Equal amounts of protein (50ug) were boiled at 100°C for five minutes, separated on
8% sodium dodecyl sulfate (SDS)- polyacrylamide gel electrophoresis (PAGE),
transferred to PVDF membrane at 100 volts at 4°C and blocked with either 5% BSA or
5% Milk dissolved in Tris-base with .05% Tween 20 (TBST).
Cell lysates were subjected to immunoblot analysis using the following
antibodies: anti-pSRC Y416, anti-pAKTS473, anti-pAKTS308, anti-p38 MAPK, total AKT
(Cell Signaling Technology, Inc.), CXCR1, CXCR2, pNF-κB/65 (Santa Cruz
Biotechnology, Inc.), total SRC (Oncogene Science, Inc.), pFAKY861 (Biosource, Inc.),
total FAK (BD Transduction, Inc.) and vinculin (Sigma, Inc.). Secondary antibodies
used were as follows: anti-mouse IgG-HRP and anti-rabbit IgG-HRP (Bio-Rad, Inc.).
The dilutions for primary antibodies used were 1:1000 with the exception of Vinculin
1:10,000. The dilutions for secondary antibodies used were 1:3000. The primary
antibodies were applied overnight at 4°C, membranes were washed 5 times for 5
minutes at room temperature, secondary antibodies were applied to membranes for 1
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hour at room temperature, membranes were washed again 5 times for 5 minutes at room
temperature. After application of the enhanced chemiluminescence reagent ECL
(Pierce, Inc.), blots were visualized on X-ray films. Experiments were completed at
least twice.
Immunoprecipitation
Immunoprecipitation method was used to determine expression of the IL-8
receptors, CXCR1 and CXCR2. Cell lysates were extracted using previously described
methods (107). To immunoprecipitate CXCR1, 4 ug of CXCR1 or CXCR2 antibody
(Santa Cruz, Inc.) was added to 1mg of cell lysate and incubated overnight on a rotator
at 4°C. Protein A-Agarose beads (Roche Applied Sciences) were used to form a
complex between the CXCR1 receptor with high affinity for rabbit IgG and Protein GAgarose beads (Thermo Scientific Pierce) were used to form a complex between the
CXCR2 receptor with high affinity for mouse IgG. To prepare agarose beads, 50ul of
Protein A or G beads were centrifuged at 12,000rpm for 20 seconds to remove
supernatant. Beads were resuspended in 50ul RIPA buffer, lysate-antibody samples
were added to the resuspended beads and samples were incubated for 2 hours on a
rotator at 4°C. Samples were then centrifuged at 5,000rpm for 2 min at room
temperature and supernatant was aspirated. To wash the lysate-antibody complex
samples, ICKA wash buffer was added and samples were centrifuged for 5,000rpm for
2 min at room temperature. This step was repeated three times and 1X Lamelli sample
buffer was added to samples and boiled for 5 minutes at 100°C. The supernatants were
loaded onto a 6% SDS-PAGE gel and the remaining immunoblot was performed using
the methods in the immunoblot section.
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Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR) and Quantitative
Real Time-PCR (qRT-PCR)
Total RNA was isolated from cells using the RNeasy Mini Kit (Qiagen)
manufacturer’s protocol. Purified RNA was subjected to RT-PCR and qRT-PCR using
the Peltier Thermal Cycler (MJ Research) and the MX3000P™ Real-Time PCR System
(Stratagene). The following primers were used: CXCR1F- 5’- GCTGTTGAGGTAC
CTCCAAG-3’, CXCR1R- 5’ AGTTCTTGGCACGTCATCG-3’; CXCR2F-5’-TCTG
CTACGGATTCACCCTG-3’,CXCR2R-5’ ACATTCCTGTGCAAG GTGG-3’; IL-8F5’ ATGACTTCCAAGCTGGCCGT-3’, IL-8R- 5’CCTCTTCAAAAACTTCTCCA
CACC-3’. All PCR reactions were completed using glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) as a control using the following primers: GAPDHF5’GAGGGGGCAGGGGACCTG-3’,GAPDHR- 5’GGGAAG TGGGGGCTGGG
AAG3’. For reverse transcriptase, 1ug of RNA was transcribed into cDNA using the
Thermoscript™ RT-PCR System following the manufacturer’s protocol. PCR was
completed with initial denaturation at 95°C for 5 minutes, 25 cycles of denaturation
(95°C for 2 min), annealing (63°C (IL-8), 59°C (CXCR1/2), 62°C (GAPDH) for 45
seconds), extension (72°C for 2 minutes), and final extension (72°C for 10 minutes)
after all cycles completed. PCR samples were analyzed on a 1.5% agarose gel
containing ethidium bromide using diluted Biorad™ Tris/Acetic
Acid/Ethylenediaminetetraacetic acid (EDTA) (TAE) buffer. Bands were visualized by
Bio-Rad Gel Doc 2000 (BioRad, Inc.).
qRT-PCR was performed by extracting RNA using the aforementioned
procedure. One microgram of RNA was transcribed into cDNA using TaqMan®
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Universal PCR Master Mix (Applied Biosystems) according to the manufacturer’s
protocol. The PCR reaction was made using TaqMan Gene Expression Assays (Applied
Biosystems) for IL-8 (Hs00174103_m1) and GAPDH (HS02758991_g1) following the
manufacturer’s protocol. Quantitative PCR was completed using the following cycling
program: 60°C for 15 minutes, 95°C for 2 min., 40 cycles of 95°C for 15 seconds and
60°C for 30 seconds. Gene expression was quantified relative to the GAPDH
housekeeping gene. Threshold cycle (Ct) was determined for all cell lines and the
relative level of transcript (2∆Ct) was determined by the following formula: 2(Sample IL-8 CtGAPDH of Sample Ct)

and differences between cell lines were obtained using the formula,

1/2∆Ct. Experiments were completed in triplicate and completed at least twice.
Enzyme-linked immunosorbent assay (ELISA)
To obtain conditioned media for ELISA, 50,000 viable cells were plated and
the appropriate serum free medium was added for 24 or 48 hours. Conditioned media
were subjected to centrifugation and stored at -20°C or used immediately. Remaining
viable cells were detected by trypan blue exclusion and counted using the ViCell™ XR
Cell Viability Analyzer (Beckman Coulter). For the ELISA, each conditioned medium
was assayed for IL-8 using Quantikine® ELISA Human CXCL8/IL-8 Immunoassay
(Research Diagnostics, Inc.: R&D Systems) according to the manufacturer’s protocol,
and IL-8 levels were determined by comparison of absorbance of IL-8 protein to the
standard curve. This system utilizes trypan blue exclusion to determine the population
of viable cells and reports viable cells and total cell populations. These and subsequent
experiments use viable cell counts for conducting experiments. The production of IL-8
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was calculated to relative cell number. Experiments were completed in triplicate and
completed at least twice.
In vitro Cell Proliferation Assay
To determine the rate of cell proliferation, cells were incubated for 12, 24, 48
or 72 hours with changes of medium every 48 hours. At each time point, cells were
trypsinized and neutralized with growth medium, and viable cells were counted using
the ViCell™ XR Cell Viability Analyzer. Cells were counted in triplicate and the
experiments were repeated at least once.
To determine the effect of rhIL-8 on rate of cell proliferation, rhIL-8 was
administered at concentrations of 10, 25, 50 or 100ng/ml in serum-free medium for 24
hours. Viable cells were determined by using the colorimetric CellTiter 96® AQueous
Non-Radioactive Cell Proliferation Assay (MTS) (Promega). Cells were counted in
triplicate and the experiments repeated at least once.
In Vitro Migration and Invasion Assays
Migration and invasion assays were performed using boyden chamber inserts
with 8.0µm-pore sizes. Invasion assays were performed using similar boyden chamber
inserts with a BD Matrigel™ basement membrane matrix mimicking a physiological
basement membrane. Briefly, 50,000 cells were plated in the top insert of a 24-well
plate, and serum-free medium, growth medium or serum-free medium with recombinant
IL-8 (rhIL-8) was added to the bottom chamber. After 18 hours, inserts were removed
from the chamber, non-migratory cells were removed and migrated cells on the bottom
of the insert were fixed and stained with HEMA 3® Stain Set (Fisher Scientific
Company) according to the manufacturer’s protocol. After staining, migratory or
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invasive cells were counted at 10x magnification in five random fields; counts were
averaged for each insert and represented as cells migrated or invaded.
To determine the effects of dasatanib on migration and invasion, either 50nM
or 100nM of dasatanib was added to serum- free medium in the bottom chamber, and
inserts were placed atop wells for 18 hours. Migration and invasion were determined
using the protocol already described. Experiments were completed in triplicate at least
once.
In vitro Co-culture migration and invasion assay of prostate cancer cells to
immortalized human bone stromal cells
To produce conditioned medium from stromal cells, 50,000 HS5 cells were
plated in 24-well plates overnight, and serum-free medium was added to cells for 24 or
48 hours. Conditioned medium was used immediately or subjected to centrifugation
and stored at -80°C.
To determine if stromal cell-conditioned medium affects migration and
invasion of PCa cells, PC3 or PC3-MM2shIL-8 cells were plated in 24-well inserts in
growth medium overnight. After the growth medium was removed and the cells
washed, HS5 conditioned medium was placed in the bottom chambers of the plates and
the inserts with PCa cells were placed on top of the bottom chambers for 12-24 hours.
To determine the number of migrated or invaded cells, fixing, staining and counting
were performed as described in the migration and invasion assay section. This assay
was also completed with HS5 nontargeting control cells and shIL-8-cell conditioned
medium. Each experiment was performed in triplicate.
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In vitro Co-culture of immortalized human bone stromal cell conditioned media
with prostate cancer cells
We tested whether co-culture of stromal cell conditioned medium with PCa
cells affects Src activity. Briefly, HS5 or HS5shIL-8 cells were plated in 100 cm2
dishes, serum-free medium was added and conditioned medium was collected after 24
or 48 hours, subjected to centrifugation and stored at -80°C or used immediately. Each
stromal cell-conditioned medium was placed on PC3 or PC3-MM2shIL-8 cells for 10,
15 or 60 minutes. Cell lysates were subjected to immunoblot analysis using the
procedure already described.
Orthotopic implantation of tumor cells
Male athymic nude mice were purchased from the Department of Veterinary
Medicine and Surgery Rodent Facility at MD Anderson Cancer Center. Animals were
housed in pathogen-free conditions in the Research Animal Support Facility (RASF) at
MDACC and used according to the institutional guidelines. In order to monitor PC3
cells in vivo, PC3 cells were plated in 12 well plates and infected with pre-made Renilla
Luciferase-RFP fusion lentiviral particles (PC3RL) purchased from GenTarget, Inc
(#LVP369). Briefly, 50ul of lentiviral particles were added to PC3 cells in fresh growth
media and allowed to incubate for 48hrs. The transduction rate was determined by
fluorescence imaging and sorted using MDACC Flow Cytometry and Cellular Imaging
Core Facility.
Prior to orthotopic implantation, confluent PC3RL cells, HS5NT and
HS5shIL-8 cells were detached and neutralized with growth media. A total of 5x106
cells for the PC3RL group, 10x106 cells for the PC3RL:HS5NT group and 10x106 cells
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for the PC3RL:HS5shIL-8 group were counted and subjected to centrifugation. Cells
were resuspended in serum free DMEM in the following groups: .25x106 of PC3RL
cells in 25ul, .25x106 of PC3RL cells plus .25x106 of HS5NT cells in 25ul and .25x106
of PC3RL cells plus .25x106 of HS5shIL-8 cells in 25ul.
For orthotopic implantations, male athymic nude mice (ages 3-5 wk) were
anesthetized using Isoflurane. After which, mice were placed in a supine position and
an incision was made in the lower abdomen. After prostate exteriorization, 25ul of
SFM containing either PC3RL, PC3RL:HS5NT or PC3RL:HS5shIL-8 were injected
into the lateral lobe of the prostate. Surgical clips were used to close the wound and
removed one week post-surgery. To monitor tumor growth by luciferase activity, mice
were injected with 100ul of Luciferin (GoldBio,Inc.) at 2.5 mg/ml and analyzed using
the IVIS Imaging System (Caliper Life Sciences) in the Small Animal Imaging Facility
at MDACC.
Tissue Preparation
After 20 days, mice were anesthetized with Isoflurane and mice were
sacrificed. Primary tumors were excised, weighed and immediately portions were fixed
in 10% formaldehyde in phosphate buffer. Another portion was embedded in OCT
compound (Sakura Finetek) and flash frozen. The remaining portions were sealed in
microcentrifuge tubes, flash frozen in liquid nitrogen and stored in -80°C. Iliac and
renal metastases were determined by the enlarged size and opaque color observed and
metastases were harvested.
Phase I/II Dasatanib + Docetaxel Clinical Trial in Patients with Metastatic CRPC
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To determine the effects of dasatanib + docetaxel treatments in patients with
metastatic CRPC, a Phase II clinical trial was performed and the parameters that were
assessed were the maximum tolerated dose, toxicity profile and pharmacokinetics. The
patient and eligibility critieria, study design and pharmacokinetics evaluation are
outlined in detail in the study submitted by Araujo et al (211). Briefly, a small cohort of
46 patients were treated with intravenous administration of docetaxel and oral dasatanib
administration in escalated dosages for 21 days. Blood samples were collected at days
1 (docetaxel alone), 14 (dasatanib alone) and 21 (docetaxel and dasatanib). Tumor
progression was also measured using response evaluation criteria in solid tumors
(RECIST) and bone radiographic measurements were taken pre- and post-treatments to
indicate response. PSA and IL-8 levels were assessed using a cytokine platform.
Statistics
Statistical analyses were performed using GraphPad Prism 5 software
(GraphPad, Inc.). Absorbance counts from proliferation assays and cell numbers from
migration and invasion assays were compared using the Student t-test. All statistical
tests were two-sided. Statistical values are as follows: nonsignificant (ns) p > 0.05 , * p
≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 **** p ≤ 0.0001
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CHAPTER 3
THE EFFECTS OF IL-8-MEDIATED SFK ACTIVITY IN PROSTATE
CANCER IN VITRO
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Although recent androgen deprivation therapies have demonstrated promising
success in decreasing metastatic CRPC, there are still many patients that do not respond
(5). Mechanisms involved in the development of tumor resistance to these AR-targeted
therapies are unclear. As a result, there has been an increased effort in identifying
signaling mechanisms in CRPC that may be targeted in addition to AR signaling.
Of the many signaling mechanisms increased in CRPC, one protein known to
be increased in signaling mechanisms of CRPC is IL-8. Studies demonstrate that, upon
androgen withdrawal, IL-8 production is increased and, upon unresponsiveness to antiandrogen therapy, circulating IL-8 levels are increased (146,173,218). Studies also
demonstrate that increased IL-8 increases angiogenesis, migration and invasion
(175,220). These results suggest that IL-8 production enhances metastatic disease, but
it is unclear what IL-8-associated signaling molecules are involved in CRPC. Our
laboratory demonstrates that SFKs regulate IL-8 secretory levels and recent in vitro
evidence demonstrates that IL-8 stimulation of SFK activity is a partial contributor to
the survival of IL-8 expressing cells against therapeutic effects (148). This suggests
that SFKs regulate IL-8 and, in turn, IL-8 mediates SFK activity creating a feed forward
loop. However, this has not been investigated in CRPC. As a result, this chapter will
investigate if IL-8 affects Src activity in PCa cell lines and if this signaling axis affects
biological functions of metastatic disease. To accomplish this, I used the non-metastatic
LNCaP cell line and its metastatic variant, C4-2B4, and the metastatic PC3 cell line and
its highly metastatic variant, PC3-MM2. Observations from this chapter will: (1)
determine if IL-8 expression and Src activity are increased in metastatic disease, (2)
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determine how IL-8 mediates Src activity in PCa and (3) determine if IL-8 mediation of
SFK activity affects biological functions of metastatic disease.
IL-8 receptors expressed in PCa cell lines
IL-8 is known to signal through G- protein coupled receptors, CXCR1 and
CXCR2. CXCR1 is the high affinity IL-8 receptor (14,159). Binding of IL-8 to CXCR1
is primarily responsible for mediating proliferative and motility functions of tumor cells
(220). Shamaladevi et al. reports that CXCR1 contributes to changes in tumor growth
and cell proliferation, while other reports demonstrate that CXCR2 does not contribute
to tumorigenesis of PCa (186,221). These results suggest that the CXCR1 receptor is
more relevant in PCa progression. As a result, I determined CXCR1 expression in the
PCa cell lines, by examining mRNA and protein levels through RT-PCR and
immunoblot analysis in LNCaP, C4-2B4, PC3 and PC3-MM2 cell lines. First, RT-PCR
was performed to determine the level of CXCR1 mRNA expression in all PCa cell
lines. Figure 6a shows that CXCR1 mRNA is expressed in all cell lines while
displaying a decrease in mRNA expression in the PC3-MM2 cell line. Secondly,
immunoprecipitations were performed using a CXCR1 antibody and immunoblot
analysis was done to assess CXCR1 protein expression in all PCa cell lines. Figure 6b
demonstrates that there is CXCR1 protein expression in all cell lines with a decrease in
protein levels in PC3-MM2 cells. Studies, by other laboratories, demonstrate that
CXCR1 undergoes receptor internalization and/or down-regulation upon IL-8
stimulation in cells with high IL-8 levels (166). This led me to ask the question of
whether IL-8 levels are high or low in the cell models. As a result, I determined if IL-8
levels were increased in all PCa cell lines.
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FIGURE 6 CXCR1 Expression in PCa Cell Lines
A. LNCaP, C4-2B4, PC3-PC3-MM2 cell lines were grown to sub-confluence, RNA
was isolated and RT-PCR was performed using primer sequences targeting CXCR1. B.
Cells were grown to sub-confluence, immunoprecipitations were performed with the
anti-CXCR1 antibody and cell lysates were subjected to immunoblot analysis.
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IL-8 expression and protein production is increased in metastatic variants
I determined if there were differences in IL-8 mRNA expression and protein
levels amongst the PCa cell lines and their metastatic variants. To determine the
mRNA expression levels of IL-8 in PCa cell lines, qRT-PCR was performed. As shown
in Figure 7a and c, qRT-PCR demonstrated that IL-8 mRNA expression levels were
increased in the C4-2B4 cells relative to LNCaP cells and increased in the PC3-MM2
cells relative to PC3 cells (p≤0.001 and p≤0.01, respectively). To determine if IL-8
secreted levels correlated with mRNA levels, I performed an ELISA using the
conditioned media of PCa cells and quantified the results according to cell number. The
results demonstrate that IL-8 secretory levels were significantly increased in PC3-MM2
and C4-2B4 relative to their isogenic variants (p≤0.001 and p≤0.01, respectively). IL-8
levels were virtually undetectable in LNCaP cells, shown in Figure 7b and d. These
results, first, demonstrate that IL-8 mRNA expression correlates with secretory levels.
Second, the results demonstrate that there is a correlation between IL-8 levels and
metastatic potential (LNCaP<C4-2B4<PC3<PC3-MM2).
Src activity is increased in metastatic variants
While the previous data show that IL-8 levels are increased in metastatic cell
lines, our laboratory demonstrated that Src activity is increased in metastatic cells (PC3
and PC3-MM2) (107). As a result, I wanted to determine whether there was
a correlation between IL-8 levels and Src activity in PCa cell lines and their metastatic
variants. To accomplish this, immunoblot analysis was performed using
phosphorylated SFK and total Src antibodies. Immunoblot analysis demonstrated that
Src activity was significantly increased in C4-2B4 cells relative to LNCaP cells and
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FIGURE 7 IL-8 mRNA Expression and Production in PCa Cell Lines
A. LNCaP, C4-2B4, PC3 and PC3-MM2 cells were grown to subconfluence and mRNA
was isolated for qRT-PCR. IL-8 mRNA expression was assessed by qRT-PCR and
reported as IL-8 mRNA expression relative to either LNCaP or PC3 IL-8 mRNA
expression. B. Cells were seeded, serum starved and conditioned media was collected
from all cell lines. ELISA was performed to determine secretory levels of IL-8 in all
cells and reported as pg/ml of IL-8 relative to total cell number. ** p ≤ 0.01, *** p ≤
0.001
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significantly increased in PC3-MM2 cells relative to PC3 cells (shown in Figure 8a
and b). The results, first, demonstrate that Src activity is increased in the cell lines in
the following order, LNCaP<C4-2B4<PC3<PC3-MM2. Second, the results
demonstrate that although there is not a direct correlation between absolute IL-8 levels
and Src activity the highly metastatic cells have the highest Src activity and IL-8
expression.
Next, to determine if exogenous IL-8 increases Src activity in low and high
metastatic cells, I treated cell lines with 50ng/ml of recombinant IL-8 (rhIL-8) for 5, 10
and 30 minute timepoints. 50ng/ml of rhIL-8 was used as an optimal concentration
demonstrated to increase downstream signaling in PCa cell lines as determined by
previously published results (223). Addition of rhIL-8 significantly increased Src
activity by 3.5 fold in LNCaP cells, 1.7 fold in C4-2B4 and 3.1 fold in PC3 cells, shown
in Figures 9 and 10. However, there were no increases seen in the highly metastatic
PC3-MM2 cell line. These results demonstrate that IL-8 increases Src activity in nonand low metastatic PCa cells, while demonstrating IL-8 does not increase Src activity in
highly metastatic PCa cells.
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FIGURE 8 Src Activity in Low and High Metastatic PCa Cell Lines
Cell lysates from (A) LNCaP and C4-2B4 cells, (B) PC3 and PC3-MM2 cells were
subjected to immunoblot analysis. Src activity was determined by using anti-phospho
Src Y419 and Total Src antibodies.
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FIGURE 9 Effects of Exogenous IL-8 on Src Activity in the LNCaP Model
A and B. LNCaP and C4-2B4 cells were grown to subconfluence, serum starved and
treated with rhIL-8- (50ng/ml). Lysates were analyzed by immunoblot and Src activity
was determined by using anti-phospho Src Y419 and Total Src antibodies. Vinculin was
used as a loading control. ** p ≤ 0.01, *** p ≤ 0.001
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FIGURE 10 Effects of Exogenous IL-8 on Src Activity in the PC3 Model
A and B. PC3 and PC3-MM2 cells were grown to subconfluence, serum starved and
treated with rhIL-8- (50ng/ml). Lysates were analyzed by immunoblot and Src activity
was determined by using anti-phospho Src Y419 and Total Src antibodies. Vinculin was
used as a loading control. *** p ≤ 0.001
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Exogenous IL-8 increases proliferation in low metastatic variants
Past studies demonstrated that overexpression of IL-8 in LNCaP cells
increased proliferation (146, 223). However, I wanted to determine if exogenous IL-8
increases proliferation between low and high metastatic cells. Cells were plated and
rhIL-8 was added to cells at 10, 50 and 250ng/ml concentrations for 72 hours and an
MTS assay was performed. Figure 11a-c show that the LNCaP, C4-2B4 and PC3 cell
lines demonstrate increased proliferation at 72hr (p≤0.05) with 250ng/ml of rhIL-8,
while PC3-MM2 cells do not demonstrate changes in proliferation at any timepoint or
rhIL-8 concentration, shown in Figure 11d. These results, first, confirm that IL-8
induces proliferation in the non-metastatic LNCaP cells and demonstrates that IL-8
induces proliferation in low metastatic C4-2B4 and metastatic PC3 cells. Second, these
results demonstrate that IL-8 does not induce proliferation of the high metastatic cell
line, PC3-MM2, likely because of high endogenous IL-8 expression and high Src
activity, shown in Figure 7b and d Figure 8.
Exogenous IL-8 increases migration in low metastatic variants
Next, I determined if exogenous IL-8 affects migration in low and high
metastatic cells. To accomplish this, cells were allowed to migrate for 18 hours in the
absence or presence of rhIL-8 (50ng/ml). Media with 10% FBS was used as a control.
As shown in Figure 12b, migration was significantly increased in LNCaP (p≤0.01), C42B4 (p≤0.05) and PC3 (p≤0.001) cells upon addition of rhIL-8, but this effect was not
seen in the highly metastatic variant of PC3, PC3-MM2.

These results demonstrate

that IL-8 increases migration of low metastatic PCa and not the highly metastatic PCa
cell, PC3-MM2.
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FIGURE 11 Effects of Exogenous IL-8 on Proliferation of PCa Cells
A-D. LNCaP, C4-2B4, PC3 and PC3-MM2 cells were treated with 0, 10,50 and
250ng/ml of rhIL-8 in serum-free medium (SFM) or 10% FBS growth medium for 72
hours. The growth rate of viable cells was determined by MTS assay at 12, 24, 48 and
72 hour timpoints.* p ≤ 0.05, *** p ≤ 0.001
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FIGURE 12 Effects of Exogenous IL-8 on Migration of PCa Cells
A. Migration assay of LNCaP, C4-2B4, PC3 and PC3-MM2 cells migrating toward
50ng/ml of rhIL-8 in serum free media (SFM) for 18 hours. Pictures were taken of
migrated cells after fixation and staining. B. Graph of migrated cells to SFM, rhIL8/SFM or growth medium. Numbers represent five random fields of cells counted at
10x magnification. Significance of differences within cell lines were calculated and
statistics represent migration relative to SFM control. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤
0.001
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SFK inhibition reverses IL-8-mediated increases in migration of low metastatic
variants
While IL-8 increases the migration of low metastatic PCa cells, I next
determined if IL-8 mediated increases in migration were SFK-dependent. PC3 cells
were allowed to migrate in three conditions: (1) in the presence of the SFK inhibitor,
dasatanib (50nM), (2) in the presence of rhIL-8 (50ng/ml) and (3) in the presence of
dasatanib and rhIL-8 for 18 hours, shown in Figure 13a. Figure 13b shows that, as
expected, rhIL-8 significantly increased migration (p≤0.05). In the presence of
dasatanib, migration was significantly decreased (p≤0.01). However, the addition of IL8 to dasatanib-treated PC3 cells did not overcome the dasatanib-mediated decreases in
migration (p≤0.01). These results demonstrate that IL-8-mediated migration is an SFKdependent event. Previous results from our laboratory demonstrate that SFK inhibition
decreases IL-8 production. (138). Altogether, these results show IL-8 is regulated by
SFKs and, in turn, SFKs regulate IL-8 suggesting that a feed forward mechanism is
present. To determine if an IL-8-mediated feed forward loop exists, I knocked down
IL-8 in highly metastatic PCa cells.
IL-8 shRNA decreases endogenous IL-8 expression and production
For these experiments, I chose the PC3-MM2 cells because they exhibit the
highest IL-8 mRNA expression, secretory levels and Src activity amongst all PCa cells.
Knockdown of IL-8 in PC3-MM2 cells was performed by using the IL-8 shRNA
lentiviral vector kindly provided by Dr. Menashe Bar-Eli. Construction of the lentivirus
is described in the Materials and Methods section. Cells were infected with a
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FIGURE 13 Effects of SFK inhibition on IL-8-Mediated Migration
A. Migration assay of PC3 cells performed in the absence or presence of the SFK
inhibitor, dasatanib, (50nM) with or without rhIL-8 (50ng/ml), for 18 hours. Pictures
were taken of migrated cells after fixation and staining and cell were counted at 10x
magnification. B. Graph illustrates cells that have migrated in the absence or presence
of dasatanib and in the presence of rhIL-8 and dasatanib. Bars represent the average
number of cells migrated from triplicate wells. * p ≤ 0.05, ** p ≤ 0.01
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nontargeting control (GN18) or the shIL-8 vector and subjected to RT-PCR, qRT-PCR
and ELISA to determine the efficiency of the IL-8 knockdown. The nomenclature for
cells was as follows: PC3-MM2 (no vector control), PC3-MM2NT (PC3-MM2
nontargeting control) and PC3-MM2shIL-8 (PC3-MM2 IL-8 knockdown).
To determine if IL-8 knockdown was successful, first, I determined the mRNA
expression level of IL-8 in PC3-MM2shIL-8 compared to PC3-MM2 cells by qRTPCR. As shown in Figure 14a and b, IL-8 mRNA levels were significantly reduced in
PC3-MM2shIL-8 cells relative to the PC3-MM2 cells (65% of PC3-MM2; p≤0.001).
To determine if IL-8 secretory levels were inhibited, conditioned media was collected
from all cell lines for ELISA detection as described in Materials and Methods. IL-8
secretory levels were also significantly decreased, by ~55% (p≤0.001), shown in Figure
14c. Thus, the IL-8shRNA lentivirus vector could be used to examine the effects of IL8 knockdown.
IL-8 knockdown decreases Src activity and downstream targets in PCa cells
Next, I determined if IL-8 knockdown decreases SFK activity. Lysates were
subjected to immunoblot analysis and a SrcY419 specific antibody were used to detect
activity shown in Figure 15. These results demonstrate that in the PC3-MM2shIL-8
cells, Src activity was decreased by 56% relative to PC3-MM2NT cells, shown in
Figure 15a. This is the first evidence demonstrating that knockdown of IL-8 in PC3MM2 cells results in decreased SFK activity.
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FIGURE 14 Lentiviral Knockdown IL-8 in PC3-MM2
PC3-MM2 cells were infected with lentiviral IL-8 nontargeting vector (PC3-MM2 NT)
and IL-8 shRNA vector (PC3-MM2 shIL-8). A and B. RNA was isolated from PC3MM2, PC3-MM2NT and PC3-MM2shIL-8 cells and subjected to qRT-PCR using IL-8
specific primers. C. Cells were seeded, serum starved and conditioned media was
collected from cells. Secretory IL-8 levels were assessed by ELISA in PC3-MM2,
PC3-MM2NT and PC3-MM2shIL-8 cells. The results were normalized to total cell
number. *** p ≤ 0.001
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FIGURE 15 Effects of IL-8 Knockdown on Src Activity and IL-8 Signaling
PC3-MM2, PC3-MM2NT and PC3-MM2shIL-8 cells were grown to subconfluency,
lysates were extracted and analyzed by immunoblot. A. Immunoblot analysis using
antiphospho- and anti-total SFK antibodies. B. Immunoblot analysis using
antiphospho- and anti-total ERK and AKT antibodies. C. Immunoblot analysis using
pNFk-B/65 antibody and vinculin as a loading control. Densitometry was done by
quantitating the ratio of anti-phospho bands to anti-total bands or vinculin bands.
Numbers represent arbritary units normalized to no vector control.
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I also examined downstream targets important to Src and IL-8 function, such
as AKT, ERK and NF-κB as seen in Figure 15b and c. The results demonstrate that
IL-8 knockdown significantly decreases pAkt by 52%, pErk by 70% and NFk-B levels
by 90%. These observations indicate that IL-8 mediates SFK activity and downstream
targets.
IL-8 knockdown decreases biological functions of PC3-MM2 cells
To determine if knockdown of IL-8 decreases migration and invasion in PCa
cells, I performed migration and invasion assays by allowing cells to migrate for 18
hours. The results in Figure 16a and b demonstrate that knockdown of IL-8
significantly decreased migration (p ≤ 0.001). Knockdown of IL-8 also decreased
invasion (p ≤ 0.001), Figure 16c and d. These results confirm that IL-8 mediates
migration and invasion as shown by Figure 12.
IL-8 rescue vector restores IL-8 expression and Src activity in PC3-MM2shIL-8
cells
To determine if results of the IL-8 shRNA knockdown experiments were due
to specific IL-8 targeting and not due to off-target effects, an IL-8 rescue vector
(pSI/IL-8) was constructed using a PCR-based mutagenesis approach introducing point
mutations in the shRNA target region without affecting the peptide sequences. The
pSI/IL-8 rescue vector was described in Materials and Methods. For the rescue
experiments, PC3-MM2shIL-8 cells were transfected with the pSI/IL-8 vector and an
ELISA was performed to determine if IL-8 production was restored. Transfection of
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FIGURE 16 Effects of IL-8 Knockdown on Migration and Invasion
A. PC3MM2NT and PC3-MM2shIL-8 cells were plated in boyden chambers and
allowed to migrate for 18 hours. B. PC3MM2NT and PC3-MM2shIL-8 cells were
plated in boyden chambers with Matrigel coating and allowed to invade for 18 hours.
Pictures were taken of migrated (B) or invaded (D) cells after fixation, staining and
numbers represent five random fields of cells counted at 10x magnification.
Significance of differences within cell lines were calculated and statistics represent
migration or invasion relative to nontargeting (NT) control. *** p ≤ 0.001
.
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PC3-MM2shIL-8 cells with pSI/IL-8 rescue vector fully restored IL-8 production levels
relative to PC3-MM2NT cells (Figure 17a). This result demonstrates the targeting
vector does not have off-target effects.
Next, to determine if Src activity were restored, immunoblot analysis was
performed with PC3-MM2NT, PC3-MM2shIL-8 and PC3-MM2shIL-8 + rescue vector.
Figure 17b demonstrates restoration of Src activity in the PC3-MM2shIL-8 with the
pSI/IL-8 rescue vector. This experiment demonstrates that Src activity is regulated by
IL-8. These results demonstrate that there is a feed forward loop whereby IL-8
regulates Src activity and Src activity further regulates IL-8 production.
IL-8 rescue vector restores migration and invasion in sh-knockdown
To determine if rescue of IL-8 in PC3-MM2shIL-8 cells also restores
migration and invasion, migration and invasion assays were performed with the pSI/IL8 rescue vector. Figure 18 shows that, post-transfection with the IL-8 rescue vector,
migration was restored relative to nontargeting control ( p ≤ 0.001). Invasion was also
restored relative to nontargeting control (p ≤ 0.05), shown in Figure 18. These results
suggest that IL-8 is a regulator of the migratory and invasive events in the PC3-MM2
metastatic cells.
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FIGURE 17 Effects of Rescue of IL-8 in PC3-MM2shIL-8 on IL-8 Production and
Src Activity
Mutagenesis experiments were performed introducing mutations that restore the
expression of IL-8 without affecting the sh-mediated knockdown vector. PC3MM2shIL-8 cells were transfected with the pSI/IL-8 rescue vector. A. ELISA was
performed to determine the levels of IL-8 production in PC3-MM2shIL-8 and PC3MM2shIL-8+IL-8 rescue vector. B. Lysates were extracted from PC3-MM2NT, PC3MM2shIL-8 and PC3-MM2shIL-8 + IL-8 rescue vector cells and were analyzed by
immunoblot using antiphospho- or anti-total Src antibodies. Densitometry was done by
quantitating the ratio of pSrcY419 bands to the ratio of Total Src bands and numbers
represent arbritary units normalized to NT control.
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FIGURE 18 Effects of Rescue of IL-8 in PC3-MM2shIL-8 on Migration and
Invasion
A. PC3-MM2shIL-8 cells were transfected with the pSI/IL-8 rescue vector and cells
were allowed to migrate or invade for 18 hours in serum free medium. Cells migrating
or invading are reported as the average migrated or invaded cells. B. Cells were fixed,
stained and counted at 10x in five random fields* p≤0.05, *** p≤0.001
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CHAPTER 4
THE ROLE OF HS5 STROMAL-PRODUCED IL-8 ON SFK ACTIVITY AND
PROSTATE CANCER PROGRESSION IN VITRO
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PCa progresses due to changes not only in the tumor cells, but also in the
microenvironment. In vitro studies demonstrate that stromal cells play a regulatory role
in prostate carcinogenesis (77). The contributions of stromal cells in the progression of
PCa can exist by physical contact, but also by factors secreted and/or expressed by the
stromal cells, particularly cytokines. There are multiple studies, outlined in the
introduction, demonstrating that stromal factors affect PCa progression, but there is
unclear evidence regarding the role of stromal IL-8 production in metastatic disease.
Therefore, I have chosen to use a stromal IL-8 producing cell line as a model
to investigate how IL-8 production by stromal cells affects biological functions of PCa
cells in vitro. In this chapter, I used a stromal cell line, HS5, derived from bone marrow
fibroblasts, known to produce IL-8 (224). The HS5 cell line is used in this chapter to
investigate the role of stromal IL-8 production in the regulation of biological functions
of PCa cells. Observations from this chapter will: (1) determine if stromal IL-8 affects
migration and invasion of PCa cells and (2) determine if stromal IL-8 affects Src
activity of PCa cells. Results are discussed in this chapter.
HS5 stromal cells characterized by IL-8 expression and production and CXCR1
protein expression
First, to determine if the high affinity CXCR1 receptor were expressed in the
HS5 cells, CXCR1 was immunoprecipitated with an anti-CXCR1 specific antibody and
immunoblot analysis was performed. Results are shown in Figure 19. Figure 19c
shows that the CXCR1 receptor is expressed in the HS5 stromal cells. Along with
CXCR1 expression, I examined IL-8 mRNA expression and IL-8 protein levels in HS5
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FIGURE 19 IL-8 mRNA Expression and Production and CXCR1 Protein
Expression in the HS5 Stromal Cell Line
A. HS5 cells were grown to subconfluence, serum starved for 24 hours and RNA was
isolated for RT-PCR to determine IL-8 mRNA expression. B. After seeding and serum
starving HS5 cells, conditioned media from was collected and ELISA was performed to
determine levels of IL-8. C. Immunoprecipitation with anti-CXCR1 antibody and
rabbit IgG (control) was completed and immunoblot analysis was performed to
determine the expression of CXCR1.
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stromal cells by performing RT-PCR and an ELISA. Figure 19a shows that the HS5
cells express IL-8 mRNA and Figure 19b shows that HS5 cells produce high levels of
IL-8. Thus, these cells were a suitable model for studying stromal IL-8 production and
its effects on PCa cells.
Effects of HS5 stromal produced IL-8 on migration and invasion of PCa cells
Next, I determined if conditioned media from HS5 stromal cells affects
biological functions of PCa, such as migration and invasion. To accomplish this, I
collected stromal conditioned media from the HS5 cells and allowed PC3 cells to
migrate and/or invade for 18 hours. The results in Figure 20a and b demonstrate that
HS5 stromal conditioned media significantly increased the migration of PC3 cells
(p≤0.01). Results also demonstrate in Figure 20c and d that HS5 stromal conditioned
media significantly increased the invasion of PC3 cells (p≤0.01).
Knockdown of endogenous IL-8 in HS5 bone stromal cells
After demonstrating in Figure 20 that HS5 stromal conditioned media
increases biological functions of PCa cells, I determined whether the HS5 stromal
production of IL-8 contributes to these changes. To test this, I, first, knocked down IL8 in the HS5 stromal cells using the same lentiviral system utilized for knock down of
IL-8 in PC3-MM2 cells. HS5 cells were infected with the shIL-8 lentivirus (HS5shIL8) as previously described. The nomenclature for infection with the nontargeting and
shIL-8 vectors was HS5NT and HS5shIL-8, respectively. To determine if effective IL-8
knockdown was achieved, I assessed mRNA expression and secretory levels, by
performing qRT-PCR and ELISA, respectively. As shown in Figure 21a, IL-8 mRNA
expression was knocked down by 60% (p≤0.01). IL-8 secretory levels were knocked
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FIGURE 20 Effects of HS5 Stromal Conditioned Media on Migration and
Invasion of PC3 Cells
Conditioned media from HS5NT and HS5shIL-8 stromal cells was collected for use as a
chemoattractant. PC3 cells were seeded in (A and B) migration or (C and D) invasion
chambers, placed atop the HS5NT or HS5shIL-8 conditioned media and cells were
allowed to migrate or invade for 18 hours. Cells were fixed, stained, counted at 10x in
five random fields and reported as the average migrated or invaded cells. ** p≤0.01
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FIGURE 21 Lentiviral Knockdown IL-8 in HS5 Stromal Cells
HS5 cells were infected with lentivirus particles containing the IL-8 nontargeting vector
(HS5 NT) or IL-8 shRNA vector (HS5 shIL-8). A. RNA was isolated from HS5,
HS5NT and HS5shIL-8 cells and qRT-PCR analysis was performed. B. Cells were
seeded, serum starved and conditioned media was collected from cells. IL-8 production
was measured by ELISA. The results were normalized to total cell number. ** p ≤ 0.01
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down to 55% in HS5shIL-8 cells (p≤0.01), shown in Figure 21b. These results
demonstrate successful knock down of IL-8 in stromal cells.
Knockdown of IL-8 in HS5 stromal cells decreases SFK activity and downstream
targets
I next determined if IL-8 knockdown decreases SFK activity in HS5 stromal
cells. To do this, I compared SFK activity in NT and IL-8 knockdown cells by
immunoblot analysis using antibodies specific to Src Y419 activity and total Src.
Figure 22a shows that IL-8 knockdown decreased Src activity by 60% relative to HS5
cells. These results demonstrate for the first time that IL-8 regulates SFK activity in
stromal cells.
I also determined if knockdown of IL-8 decreases downstream targets
important to Src and IL-8 function, such as Akt, Erk and NFk-B. Figure 22b and c
demonstrate that IL-8 knockdown significantly decreases pAkt by 75%, pErk by 70%
and NFk-B levels by 80%. These results demonstrate that IL-8 mediates targets
downstream of IL-8 and Src.
SFK regulates IL-8 expression and Src activity in HS5 stromal cells
Next, I determined if SFKs regulate IL-8 expression and secretory levels in
HS5 stromal cells. To accomplish this, HS5 cells were treated with 10, 50, 100, 200
and 500nM of the SFK inhibitor, dasatanib. Cell lysates were subjected to immunoblot
analysis and anti-phospho and total Src antibodies were used. I observed a 75%
significant decrease in Src activity after treatment with 50nM dasatanib, while
subsequent increasing concentrations abolished Src activity (Figure 23). These results
demonstrate that SFK inhibition decreases Src activity in a dose-dependent manner in
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FIGURE 22 Effects of IL-8 knockdown in HS5 cells on Src activity and IL-8
Signaling
HS5, HS5NT and HS5shIL-8 cells were grown to subconfluency, lysates were extracted
and analyzed by immunoblot. A. Immunoblot analysis using antiphospho- and antitotal SFK antibodies. B. Immunoblot analysis using antiphospho- and anti-total ERK
and AKT antibodies. C. Immunoblot analysis using pNFk-B/65 antibody and vinculin
as a loading control. Densitometry was done by quantitating the ratio of anti-phospho
bands to anti-total bands or vinculin bands. Numbers represent arbritary units
normalized to no vector control.
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FIGURE 23 Effects of SFK Inhibition on Src Activity in HS5 Stromal Cells
SFK inhibition was performed by treating HS5 cells with dasatanib (10, 50, 100, 200
and 500nM) for 4 hours. Cell lysates were extracted and immunoblot analysis was
performed by using antiphospho- or anti-total Src antibodies and by using a vinculin
antibody as a loading control. Densitometry was done by quantitating the ratio of pSrc
Y419
bands to the ratio of Total Src/Vinculin bands and numbers represent arbritary units
normalized to DMSO control.
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HS5 stromal cells. It also demonstrates that maximal SFK inhibition occurs with 50nM
dasatanib.
Next, to determine if Src regulates IL-8 mRNA expression in HS5 stromal
cells, HS5 cells were treated with 10, 50 and 100nM of dasatanib and cells were
collected for RNA isolation and RT-PCR was performed. Conditioned media was also
collected to determine IL-8 secretory levels by ELISA. The results demonstrate that
dose-dependent treatment of HS5 cells with dasatanib decreased IL-8 mRNA
expression and secretory levels. IL-8 protein levels were significantly decreased by >
60% with 50nM and 100nM dasatanib (Figure 24b), whereas IL-8 mRNA levels were
significantly decreased by >50% at all dasatanib concentrations (Figure 24a). These
results demonstrate that SFKs regulate IL-8 expression and secretory levels in HS5
stromal cells, similarly to how regulation occurred in tumor cells. This allowed me to
test effects of stromal produced IL-8 on tumor cells.
HS5 stromal production of IL-8 increases Src activity in PCa cells
Next, I determined if stromal produced IL-8 regulates Src activity of PCa cells.
To accomplish this, conditioned media from stromal cells (HS5NT and HS5shIL-8) was
added to PCa cells with (PC3, PC3-MM2shIL-8 and PC3-MM2NT) for 10, 15 and 60
minutes. Cells were, then, subjected to immunoblot analysis and phosphorylated Src
and total Src activity was assessed. First, I determined if HS5 stromal conditioned
media increased SFK activity in low metastatic PC3 cells by adding HS5NT
conditioned media. The results, shown in Figure 25, demonstrate that HS5 stromal
conditioned media increased SFK activity in PC3 cells. I, next, determined if increased
Src activity was a result of HS5 stromal produced IL-8 by adding HS5shIL-8-
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FIGURE 24 Effects of SFK inhibition on IL-8 Expression in HS5 Stromal Cells
SFK inhibition was performed by ttreating HS5 cells with dasatanib. A. For IL-8
mRNA expression, dasatanib (10, 50 and 100nM) was added to HS5 cells for 4 hours
and RT-PCR was performed with primers targeting the IL-8 sequence. B. For ELISA,
cells were seeded, treated with dasatanib concentrations and conditioned media was
collected from cells. The results were normalized to total cell number. ** p ≤ 0.01
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FIGURE 25 Effects of HS5 Stromal Produced IL-8 on Src Activity in PC3 Cells
Conditioned media from HS5NT and HS5shIL-8 stromal cells was harvested. PC3 cells
were grown until subconfluent and serum starved for 24hours. Conditioned media from
either HS5NT and HS5shIL-8 stromal cells was added to cells for 10, 15 and 60
minutes, cell lysates were extracted and immunoblot analysis was performed by using
antiphospho- or anti-total Src antibodies and by using a vinculin antibody as a loading
control. Densitometry was done by quantitating the ratio of pSrc bands to the ratio of
Total Src/Vinculin bands and numbers represent arbritary units normalized to no
treatment (0’).
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conditioned medium to PC3 cells. These results demonstrate that Src activity is
decreased with addition of HS5shIL-8. These results demonstrate that IL-8 is one factor
produced by HS5 stromal cells contributing to increases in Src activity. These results
were also observed with PC3-MM2shIL-8 cells shown in Figure 26. As a control
experiment, I determined if HS5NT or HS5shIL-8 conditioned medium affects SFK
activity in cells with high IL-8 expression and Src activity. I added the conditioned
medium to PC3-MM2NT cells using the same conditions as above. Results from this
experiment demonstrate no change in Src activity with the addition of either HS5NT or
HS5-shIL-8 conditioned medium (Figure 27). These results confirm results in Figure 9
demonstrating that exogenous IL-8 has no further effect on increasing Src activity on
highly metastatic PC3-MM2 cells. Overall, these results demonstrate that stromal
production of IL-8 increases SFK activity in PCa cells and IL-8 produced from stromal
cells.
Knockdown of IL-8 production in HS5 stromal cells decreases migration and
invasion of PCa cells
Next, I determined if stromal production of IL-8 affects migration and
invasion. Conditioned medium from HS5NT and HS5shIL-8 cells was used as a
chemoattractant and migration and invasion assays were performed. To determine if
HS5 stromal conditioned medium increases migration of PC3 cells, HS5NT conditioned
medium was used a chemoattractant. As shown in Figure 28a and b, HS5NT
conditioned medium significantly increased migration of low-metastatic, PC3 cells
(p≤0.01). Next, I determined if HS5 stromal cells producing less IL-8 decreases
migration of PC3 cells by using HS5shIL-8 cell-conditioned medium as a
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FIGURE 26 Effects of HS5 Stromal Produced IL-8 on Src Activity in PC3MM2shIL-8 Cells
Conditioned media from HS5NT and HS5shIL-8 stromal cells was harvested. PC3MM2shIL-8 cells were grown until subconfluency and serum starved for 24hours.
Conditioned media from either HS5NT and HS5shIL-8 stromal cells was added to cells
for 10, 15 and 60 minutes, cell lysates were extracted and immunoblot analysis was
performed by using antiphospho- or anti-total Src antibodies and by using a vinculin
antibody as a loading control. Densitometry was done by quantitating the ratio of pSrc
bands to the ratio of Total Src/Vinculin bands and numbers represent arbritary units
normalized to no treatment (0’).
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FIGURE 27 Effects of HS5 Stromal Produced IL-8 on Src Activity in PC3-MM2
Nontargeting Cells
Conditioned media from HS5NT and HS5shIL-8 stromal cells was harvested. PC3MM2NT cells were grown until subconfluency and serum starved for 24hours.
Conditioned media from either HS5NT and HS5shIL-8 stromal cells was added to cells
for 10, 15 and 60 minutes, cell lysates were extracted and immunoblot analysis was
performed by using antiphospho- or anti-total Src antibodies and by using a vinculin
antibody as a loading control. Densitometry was done by quantitating the ratio of pSrc
bands to the ratio of Total Src/Vinculin bands and numbers represent arbritary units
normalized to no treatment (0’).
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FIGURE 28 Effects of HS5 Stromal Conditioned Media on Migration and
Invasion of PC3 Cells
Conditioned media from HS5NT and HS5shIL-8 stromal cells was harvested. PC3 cells
were seeded in (A and B) migration or (C and D) invasion chambers, chambers were
placed atop the conditioned media (HS5NT or HS5shIL-8) and allowed to migrate or
invade for 18 hours. Cells were fixed, stained, counted at 10x magnification in five
random fields and reported as the average migrated or invaded cells. * p≤0.05, **
p≤0.01
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chemoattractant. The results demonstrate that HS5 stromal cells producing less IL-8
significantly decreased migration relative to co-culture of PC3 cells with HS5NT cellconditioned medium (p≤0.05).

An invasion assay performed under the same

conditions showed similar results, as seen in the right panel of Figure 28c and d.
Figure 29a-d demonstrates that migration and invasion were also significantly
decreased when PC3-MM2shIL-8 cells were co-cultured with HS5shIL-8 cell
conditioned medium relative to HS5NT cell conditioned medium (p≤0.01). These
results demonstrate that HS5 stromal production of IL-8 affects migration and invasion
of PCa cells.
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FIGURE 29 Effects of HS5 Stromal Conditioned Media on Migration and
Invasion of PC3-MM2shIL-8 Cells
Conditioned media from HS5NT and HS5shIL-8 stromal cells was harvested. PC3MM2shIL-8 cells were seeded in (A and B) migration or (C and D) invasion chambers,
chambers were placed atop the conditioned media (HS5NT or HS5shIL-8) and allowed
to migrate or invade for 18 hours. Cells were fixed, stained, counted at 10x in five
random fields and reported as the average migrated or invaded cells. * p≤0.05, **
p≤0.01
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CHAPTER 5
THE ROLE OF HS5 STROMAL-PRODUCED IL-8 IN TUMOR GROWTH AND
METASTATIC POTENTIAL OF PROSTATE CANCER IN VIVO
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PCa progression to metastatic disease is a result of multiple factors produced
by the tumor and by the stromal microenvironment.

There is in vivo evidence

supporting the role of IL-8 tumor production in PCa progression whereby
overexpression of IL-8 in LNCaP cells increases tumor growth and microvessel density
(146).

However, we know that stromal production of IL-8 contributes to PCa

progression, as evidenced by chapter 4, where I demonstrate that stromal production of
IL-8 is one factor increasing the migration and invasion of PCa cells in vitro. To date,
there are no current in vivo models addressing if stromal production of IL-8 contributes
to the metastatic potential of PCa. As a result, this chapter will assess if stromal IL-8
production affects PCa growth and metastatic incidence by performing co-inoculations
with stromal cells and PCa cells. Observations from this chapter: (1) determines if the
tumor-stromal interaction contributes to metastatic potential in vivo (2) determines if
stromal IL-8 contributes to metastatic potential of PCa in vivo.
Orthotopic co-inoculation of HS5 stromal cells and PCa cells
This study was designed to determine if co-inoculation of stromal cells and
PCa cells affects tumor growth and metastatic incidence. For co-inoculations, low
metastatic PC3 cells and HS5 stromal cells (NT or shIL-8) were injected into the
prostate of athymic nude mice in the following ratios: .25x106 of PC3 cells for Group
1, .25x106 of PC3 cells: .25x106 of HS5NT cells for Group 2 and .25x106 of PC3 cells:
.25x106 of HS5shIL-8 cells for Group 3 with an n=10 for each group. Tumors in mice
were monitored by luciferase activity detected by bioluminescence imaging.
First, I determined the viability of the co-inoculation post-injection by
culturing the stromal-prostate cancer cell combination in vitro and monitoring the
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growth and viability for one week. Figure 30 shows a graph and representative pictures
of the PC3:HS5 combination group from day 3 and 6 demonstrating that cells are
viable.
Effects of orthotopic co-inoculation of HS5 stromal cells and PCa cells on tumor
growth and weight
To assess tumor growth, mice were monitored every three days according to in
vivo bioluminescence imaging using IVIS™-100 (Xenogen Co.) for changes in tumor
growth and luciferase activity was used as a parameter of tumor growth. Figure 31
displays representative images of tumors in each mouse. After injection of luciferin,
mice were anesthesized, placed in the bioluminescence imager and luciferase activity
was measured. The red circles, in Figure 31a-c, represent the region of interest (ROI)
encompassing the entire region of luciferase activity and the numbers represent
luciferase activity within that region.
First, I determined if stromal cells increase tumor growth of PCa cells. As
shown in Figure 32, there was a consistent increase in luciferase activity in all groups
showing consistent tumor growth. The results also demonstrate that there were no
significant differences in luciferase activity amongst different groups from day 0 until
day 14. This result demonstrates that tumors grew similarly among all groups from day
0 to 14. At day 14, there was a significant increase in luciferase activity in the
PC3:HS5NT group relative to PC3 alone group (p≤0.05), while there was no significant
difference between PC3:HS5shIL-8 group relative to PC3 alone group. This
demonstrates that stromal cells increase tumor growth of PCa cells as measured by
luciferase activity.
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FIGURE 30 Post-injection effects of Cell Viability and Growth with Stromal Cell
and PCa Cells
Directly after co-inoculations of HS5 stromal cells and PC3/RFP luciferase labeled
cells, cells were seeded together, counted and monitored for 6 days in culture. A. Cells
were counted on days 3 and 6 and viable PC3 and HS5 cells were plotted in the graph.
B. Pictures shown are representative of day 6 before sorting and counting cells. Pictures
were taken at 4x magnification.
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FIGURE 31 Determination of Luciferase Activity in Mice by in vivo
Bioluminescence Imaging
Tumor growth was monitored by bioluminescence imaging mice every three days.
Mice were injected with luciferin (20mg/ml) and placed under anesthesia. Mice were
placed in the IVIS-100 Xenogen imager and luciferase activity was measured. Pictures
were taken indicating luminescence value according to scale on right and region of
interest (ROI) was indicated encompassing the entire region of luciferase activity. The
luciferase values were calculated and used as a measurement of growth for each mice in
each group.
The representative mice are as follows: (A) mouse in PC3 group, (B) mouse in
PC3:HS5NT group and (C) mouse in PC3:HS5shIL-8.
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FIGURE 32 Effects of HS5 Stromal Produced IL-8 on Tumor Growth
After intraprostatic injections of PCa cells and stromal cells in mice, tumor growth was
monitored by imaging mice every two-three days, observing luciferase counts in each
mouse by measuring the region of interest (ROI) of the tumor for each mouse.
, * p≤0.05,** p≤0.01
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Next, I assessed whether stromal cells producing IL-8 affects tumor growth.
The results demonstrate that, at day 14, there was a significant increase in luciferase
activity in the PC3:HS5NT group relative to PC3:HS5shIL-8 group (p≤0.05). There
was a larger increase seen at day 18 demonstrating that HS5 stromal produced IL-8
increases tumor growth.
Co-inoculation of HS5 stromal cells and tumor cells increases tumor weight
After termination of the experiment, tumor weights were measured. The
average tumor weights were as follows: 126mg for PC3 group, 193mg for PC3:HS5NT
group and 169 for PC3:HS5shIL-8 group. First, I determined if co-inoculation of PC3
cells and HS5 stromal cells increases tumor weight. The results demonstrate that there
was a significant increase in tumor weight between the PC3:HS5NT group and PC3
alone (p≤0.0019). This result demonstrates that the tumor-stromal interaction
contributes to tumor growth and suggests that HS5 stromal production of IL-8
contributes to increased tumor growth.
To determine if IL-8 production in stromal cells increases tumor weight, I
compared the changes in tumor weights between the PC3:HS5NT and PC3:HS5shIL-8
groups. There was a significant decrease in the PC3:HS5shIL-8 tumor weights relative
to PC3:HS5NT tumor weights (p≥0.05) demonstrating that stromal production of IL-8
contributes to tumor weight in vivo. Results also demonstrate that PC3:HS5shIL-8
tumor weights are significantly higher than PC3 alone (p≤0.0363), shown in Table 1.
This result demonstrates that stromal cells producing less IL-8 increase tumor weights
compared tumor cells alone suggesting that, expectantly, other factors contribute to
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TABLE 1 Effects of Stromal Production of IL-8 on Primary Tumor Weight of
PC3 cells in an Orthotopic Mouse Model
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tumor weight. Overall, these results demonstrate that stromal production of IL-8 is one
factor contributing to tumor weight.
Orthotopic co-inoculation of HS5 stromal cells and PCa cells increases metastatic
incidence
To assess if metastatic incidence is affected by IL-8 producing stroma, the
same groups were assessed for the presence of metastases. Mice were opened and
thoroughly examined for iliac and renal lymph node metastases. Renal and iliac lymph
nodes were observed and confirmed by H&E (107). All three mice groups had at least
one metastasis either in the renal or iliac lymph nodes shown in Table 2. Mice injected
with PC3 cells displayed on average 1.4 metastases. Mice injected with PC3:HS5NT
cells displayed on average 3.5 metastases per mouse, while mice injected with
PC3:HS5shIL-8 cells displayed on average 2.4 metastases per mouse. To determine if
HS5 stromal cells increases metastatic incidence of PC3 cells, I compared metastases
from PC3:HS5NT group and PC3 alone group. The results in Table 2 demonstrate that
co-inoculation with PC3:HS5NT significantly increased metastatic incidence relative to
PC3 alone (p=.018). These results demonstrate that co-inoculation of stromal cells with
PCa cells increases metastatic incidence.
I, next, determined whether the increases seen in metastatic incidence were due to HS5
production of IL-8. The results demonstrate that PC3:HS5shIL-8 co-inoculations
produced significantly less metastases in comparison to PC3: HS5NT (p=.018). These
results demonstrate that stromal IL-8 production contributes to metastatic incidence.
There was also a significant increase in metastatic incidence with co-inoculations of
PC3:HS5shIL-8 relative to PC3 alone (p=.0019). This result demonstrates that stromal
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TABLE 2 Effects of Stromal Production of IL-8 on Metastatic Incidence of PC3
Cells in an Orthotopic Mouse Model

~ 105 ~

cells producing less IL-8 increase metastatic incidence compared to tumor cells alone
suggesting that, expectantly, other factors contribute to metastatic incidence. Overall,
results from this experiment demonstrates that stromal cells producing IL-8 increase
metastatic incidence making IL-8 one factor involved in metastatic potential.
In addition, the co-inoculation groups (PC3:HS5NT and PC3:HS5shIL-8) were
observed to have iliac and renal lymph node metastases, while inoculation with PC3
cells alone had only iliac lymph node metastases. This finding indicates that stromal
IL-8 production alters the spectrum of lymph node metastases. Overall, this in vivo
model demonstrates, for the first time, that stromal cells producing IL-8 increase the
metastatic potential of PCa.
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CHAPTER 6
CLINICAL SIGNIFICANCE OF IL-8 SECRETION AND SFK ACTIVITY IN
METASTATIC CRPC
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In clinical practice, PSA serves as the ‘gold’ standard for the detection of PCa.
Although a frequent upward trend of PSA levels is evident in patients with advanced
disease, there seems to be no definite, linear relationship between serum PSA levels and
PCa stage or metastasis (212). This has led to controversies over its role as a biomarker
for metastatic disease and suggests that it may instead better serve as a marker of
predisposition to abnormalities of the prostate. As a result, the investigation of other
markers, such as IL-8, are of great interest to this thesis. Several reports demonstrate
detection of increased IL-8 in serum and tissue of patients with metastatic disease in
comparison to disease-free patients or patients exhibiting benign prostatic hyperplasia
(165,171). SFK activity is also increased in patients with metastatic PCa (129,225).
Supporting in vitro and in vivo data, from our laboratory and others, demonstrates that
IL-8 increases survival of PCa in the presence of docetaxel, while SFK inhibition by
dasatanib, in preclinical models, demonstrates decreased tumor growth and metastasis
and decreased growth of PCa in the bone (226,211). These results suggest that: (1)
increased IL-8 levels contributes to disease progression and (2) SFK inhibition may
decrease tumor progression and bone metastatic disease.
Results from my in vitro studies in Chapter 3 demonstrate that exogenous IL-8
increases PCa cell progression in an SFK-dependent mechanism. I also demonstrate in
Chapter 4 and 5 that stromal IL-8 increases PCa progression in vitro and increases the
metastatic potential of PCa in vivo. As a result, I investigated, clinically, if serum IL-8
levels in patients with metastatic CRPC are affected by dasatanib treatments.

I was

able to investigate this due to a Phase II trial with dasatanib+docetaxel in metastatic
CRPC, conducted at MDACC by Dr. John Araujo. This clinical trial aimed to determine
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if dasatanib alone or dasatanib+docetaxel treatments decreases metastatic CRPC.
Additional studies from this trial were to determine if PSA, bone turnover markers and
IL-8 serum levels were changed. Observations from this study: (1) determined if
patients with metastatic CRPC responding to SFK inhibition have decreased serum IL-8
levels and (2) determined if the changes in IL-8 levels correlates with PSA levels.
Clinical administration of dasatanib decreases IL-8 levels in patients with
metastatic CRPC
This Phase I/II trial was designed to determine if dasatanib decreased
metastatic CRPC by using bone radiographic measurements and PSA levels as a
measure of response. I was interested in determining whether IL-8 levels were a better
predictor of response in comparison to PSA levels. First, to determine if dasatanib
decreases IL-8 levels in patients with metastatic CRPC, serum samples were collected
at the following timepoints: before any treatments as a control and at day 21
constituting cycle 2/dasatanib+docetaxel. Samples were split into two groups- patients
that responded to treatment and those that did not respond (responders vs. nonresponders). ELISA was performed with all samples to determine the levels of serum
IL-8 and PSA. I, first, determined if PSA levels predicted response. The results, in
Figure 33b, demonstrate that PSA levels in responders were decreased and PSA levels
in non-responding patients were also decreased. These results demonstrate that PSA
levels of responding patients mimicked the PSA levels of those patients who did not
respond. Next, I wanted to determine if IL-8 levels predicted response. Figure 33a
demonstrates that IL-8 levels in responders were decreased, whereas IL-8 levels in nonresponders remained elevated. These results demonstrate that IL-8 may be a better
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FIGURE 33 Effects of Phase I/II l Dasatanib + Docetaxel ClinicaTrial on IL-8
and PSA Production in Bone Metastatic Prostate CRPC
Serum samples collected from patients with bone metastatic PCa undergoing dasatanib
+ docetaxel treatments were assessed by radiographic measurements and ELISA was
performed for PSA and IL-8 production. PSA and bone radiographic measurements
were used as parameters of response. (A) IL-8 and (B) PSA serum levels in responders
and non-responding patients after treatments. The waterfall plot illustrates responders
(patients which do not progress on treatment) and non-responders (patients which
progress on treatment). Blue bars represent responders and orange bars represent nonresponders.
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predictor of response for patients with metastatic CRPC. Although a wider study has
been conducted and is pending, these results suggest that patients with metastatic
disease exhibiting high IL-8 levels could be selected for dasatinib+docetaxel
combination therapy.
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CHAPTER 7
DISCUSSION
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Protein tyrosine kinases signal through multiple pathways leading to
subsequent changes in biological functions of PCa. One well-studied kinase family
mediating these signaling pathways are SFKs, outlined in chapter 1. Through extensive
studies, from our laboratory and others, we have demonstrated that increased SFK
activation results in deregulation of migration, invasion, apoptosis, angiogenesis,
proliferation and survival. Work by Park et al. demonstrates that SFKs play differential
roles in PCa progression which has contributed to investigations providing a better
understanding of the biological roles of SFK members and how they contribute to tumor
progression.
As outlined in the Introduction, SFKs constitute nine family members of which
three are ubiquitously expressed (Src, Yes and Fyn) and the remaining members are
expressed in a tissue-specific manner.

Src has been one of the most widely studied

SFK members and has been shown to be increased in multiple cancers. In vitro
evidence demonstrates that Src contributes to survival, migration and invasion in the
progression of cancer. In vivo studies demonstrate that Src activation is a mediator of
tumor progression in multiple cancers, but it was unclear whether Src activation was a
contributor to progression of PCa to metastatic disease (127,131).
To better understand how Src activation contributes to metastatic disease, there
has been an increased effort in the investigation of signaling factors regulating Src
activity. We have learned that Src activity is not a result of direct activation by
extracellular signals, but by activated PTKs, GFRs, GPCRs and integrins, outlined in
the Introduction. However, there is less evidence describing a role for GPCRs and
GPCR ligands in Src activation in PCa. This is important because there are studies
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demonstrating that some GPCR ligands, which can also be classified as cytokines,
contribute to PCa progression.
Of the many cytokines contributing to PCa progression, IL-8 is one factor that
has been implicated in, not only, PCa progression, but in metastatic disease, due to its
overexpression. In addition, similar to Src, we know that IL-8 mediates biological
functions, such as angiogenesis, migration and invasion in PCa and, likewise, there is
less information regarding signaling mechanisms regulating these biological functions.
As a result, the investigation of pathways regulating IL-8 expression and Src activation
are, currently, being studied as two separate signaling mediators of PCa progression.
However, our laboratory provides evidence that Src regulates IL-8 production in PCa
cells and, more recent studies, suggest that IL-8 activates PTKs, Src and FAK, to induce
migration of PCa cells (138,147). These results suggest that the signaling mechanisms
of Src and IL-8 are, not entirely exclusive, and that regulation of Src activation may be
associated with IL-8 signaling in PCa. This becomes important because, although, we
know that IL-8 signaling is increased in PCa, IL-8 signaling by cells in the
microenvironment, such as stromal cells contributes to tumor progression.
So, it is possible that IL-8 signaling may also contribute to signaling
mechanisms, such as SFK activity, and this mechanism may contribute to increases in
PCa progression to metastatic disease. Delineation of whether IL-8 mediates SFK
activity in PCa, either tumor-mediated or stromal-mediated, could also provide another
mechanism of increased SFK activity in PCa progression.
The effects of IL-8-mediated SFK activity in metastatic prostate cancer in vitro
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Previous studies demonstrate that IL-8 and Src, individually, increase
metastatic properties of PCa as well as Src (107,146). Studies from our laboratory
demonstrate that Src regulates IL-8 secretion (138). However, there was no clear
understanding of whether Src regulation of IL-8 secretion results in Src activation and
whether this contributes to migration and invasion. Studies in Chapter 3 determined
that a feed-forward loop in PCa exists whereby IL-8 increased SFK activity increases
IL-8 production and expression, which in turn increases IL-8 activity. I also determined
that this feed forward loop contributes to migration and invasion of non-metastatic and
low metastatic PCa cells.
To determine how IL-8 affected SFK activity, I first determined that the high
affinity IL-8 receptor, CXCR1, was present in all cell lines (Figure 6). Expression of
CXCR1 was decreased in the highly metastatic PC3-MM2 cells. This result may be
explained by studies showing that higher IL-8 levels correlates with rapid
internalization of the CXCR1 receptor resulting in decreased CXCR1 expression (221).
So, it is likely that the decrease observed in PC3-MM2 is due to the presence of high
IL-8 expression and secretory levels in comparison to the other PCa cell lines (Figure
7).
In addition to PC3-MM2 cells having the highest IL-8 levels, they also
expressed the highest SFK activity in comparison to the other PCa cell lines (Figure 8).
While the levels of IL-8 do not directly correlate with levels of SFK activity, the trend
of increased secretion and expression of IL-8 and increased Src activity in PC3-MM2
cells is striking. However, one explanation for there not being a direct correlation may
be because IL-8 receptor does not directly associate with SFKs. There is no
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information suggesting that IL-8 binding to the CXCR1 receptor elicits direct activation
of SFKs. There are numerous reports demonstrating that RTKs activate SFKs, outlined
in the introduction. It is likely that there is crosstalk between CXCR1 and RTKs
resulting in SFK activation. This is supported by evidence demonstrating that IL-8
binding of CXCR1 promotes the transactivation of RTKs, such as EGFR in ovarian
cancer and VEGFR in endothelial cells (175). While EGFR plays less of a role in PCa,
VEGFR, PDGFR, MET, IGF-1R and AXL activation, to name a few, have been shown
to induce SFK activation in PCa. It would be interesting to investigate whether IL8/CXCR1 signaling promotes transactivation of these RTKs and whether there are other
unknown upstream signaling factors involved in IL-8-mediated SFK activity.
While increased IL-8 expression and Src activity are, individually, known to
increase progression, I showed that IL-8 and Src function in the same signaling pathway
to increase metastatic properties of PCa. Specifically, I demonstrated that IL-8
stimulation increases SFK activity and migration and proliferation of non-, low and
moderately metastatic PCa cells (Figures 9-12), but not that of the highly metastatic
PC3-MM2 cells. IL-8 has also been shown to increase PCa cell SFK activity,
proliferation and migration in non- to low metastatic PCa cells, while the results from
highly metastatic PC3-MM2 cells have never been reported (146,223). One explanation
for the unresponsiveness of PC3-MM2 cells to further IL-8 stimulation may be due to
their intrinsic high production of IL-8 (Figure 6). In terms of migration, this
explanation is supported by Schraufstatter et al. demonstrating that IL-8 stimulation
with 30nM or 100nM has the same effect on migration of high IL-8 producing cells
suggesting that IL-8 does not have any further effect on migration beyond these
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concentrations of IL-8 (227). In addition, Park et al. demonstrated that two SFK
members, Src and Lyn, contribute to PCa progression through differential biological
roles. Their work shows that Src primarily contributes to migration and invasion, while
Lyn contributes to proliferation in PCa cells (107). It is possible that IL-8-mediated
changes in Src activity contribute to migration and invasion of PCa, while IL-8
mediated changes in Lyn activity contribute to the proliferation of PCa cells would
require further studies. Another explanation for the changes in proliferation stems from
studies demonstrating that IL-8-mediated expression of cyclin D1, proliferative marker,
is a contributor to the proliferation of PCa cells (146). Further studies will need to be
done to determine whether the significant but minor changes in proliferation are due to
IL-8-mediated Lyn activation in PCa as well as cyclin D1. While studies demonstrate
that IL-8 does not play a role in the proliferation of other cancers, such as melanoma
and lung cancer, my studies along with others demonstrate that IL-8 is a contributing
factor to the proliferation of low metastatic PCa (147,185,223). However, I note that
IL-8’s role in increasing proliferation, while significant are small whereas there were
major increases in migration and invasion.
Thus far, I demonstrated that IL-8 production and Src activity are increased in
the highly metastatic PC3-MM2 cells and additional IL-8 does not increase Src activity
and biological functions in these cells. This work demonstrates that one mechanism
contributing to the increases in metastatic properties of PCa is through IL-8 increasing
SFK activity in vitro. Likewise, depletion of IL-8 should result in decreased SFK
activity, migration and invasion. To test this possibility, I used a lentiviral system to
knockdown IL-8 in PC3-MM2 cells (Figure 14). I demonstrate that lentiviral
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knockdown of IL-8 decreases Src activity (Figure 15a). In addition, I demonstrate that
targets, integral to IL-8 signaling, such as Akt and Erk, are also decreased, while the
well-known IL-8 transcription factor, NFk-B, is decreased as well (Figure 15b-c).
Many studies provide evidence demonstrating that IL-8 signaling increases Akt and Erk
activation in multiple cancer cells supporting my current results (229). While there are
other mechanisms of decreasing IL-8 production, such as the use of IL-8 neutralizing
antibodies, this study aimed to deplete endogenous levels of IL-8 in a stable context
rather than deplete the production of IL-8 (250,251). The use of neutralizing antibodies
are beneficial and would be useful in future experiments.
Surprisingly, there was also a 90% decrease in the phosphorylation of NFk-B
at p65 after knock down of IL-8 in PC3-MM2 cells. These results are supported by
studies from Singh et al. demonstrating that depletion of IL-8 decreases NFk-B activity,
and Wilson et al. showing that, upon IL-8 overexpresssion, IL-8 increases NFk-B
activity (174,229). While these studies demonstrate that NFk-B activity is regulated by
an IL-8-mediated signaling mechanism, it is possible that IL-8-mediated SFK activation
contributes to NFk-B activation. An earlier study demonstrates that SFK-deficient B
cells (either Blk -/-, Fyn -/- or Lyn-/-) lack proper IkB phosphorylation and display
decreased NF-kB DNA binding activity demonstrating that NFkB activation is, in part,
SFK-dependent (230). Future studies would need to be performed to determine if SFK
activation mediates NFk-B activity as opposed to expression in PCa cells. It would also
be important to determine NFk-B activity in my system by performing an activity assay
or assessing whether phosphorylation of proteins involved in NFk-B sequestration, such
as IkB members, are associated with NFk-B. The observed reductions in NFk-B may,
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partly, explain the feed forward loop because if Src activation is decreased upon IL-8
depletion and contributes to decreased NFk-B function than less IL-8 secretion would
be expected.
While NFk-B is an essential transcriptional regulator of IL-8 in PCa, evidence
suggests that other transcriptional regulator, STATs, may also regulate IL-8 expression
(138,231). This result is supported by a previous study from our laboratory
demonstrating that Src activation leads to STAT3 activation, binding to the IL-8
promoter and increased IL-8 secretion (138). More recently, Okutani et al.
demonstrates that STAT5 activation induces IL-8 secretion, STAT5 is also directly
phosphorylated and activated as a transcription factor by Src (232). Gu et al. shows
that STAT5 activity is decreased by Src inhibition and in turn decreases metastatic
behaviors of PCa (233). It would be interesting to determine if SFK activity leads to
STAT3 or STAT5 transcriptional regulation and whether this promotes IL-8 production
and expression demonstrating another mechanism for IL-8-mediated SFK activity in
PCa cells.
Overall, this chapter provides, for the first time, a mechanism of IL-8 mediated
SFK activation whereby IL-8 stimulates SFK activation that further stimulates IL-8
production increasing migratory and invasive capabilities of metastatic PCa in vitro.
The work in this chapter suggests that further investigation into the following areas
would be beneficial in understanding PCa progression: 1) investigation of biological
functions associated with IL-8 mediated Lyn activity and 2) examining whether
STAT3- or STAT5-binding to IL-8 promoter affects transcription dependently or
independently of NFk-B transcriptional regulation.
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The role of HS5 stromal-produced IL-8 on SFK activity prostate cancer
progression in vitro
Studies in chapter 4 demonstrated a feed forward loop whereby production of
IL-8 in HS5 stromal cells increases SFK activity which in turn activates IL-8 in these
cells. I also demonstrated that, upon silencing IL-8 production in HS5 stromal cells,
SFK activation was decreased to baseline levels in PCa as were migration and invasion.
This demonstrates a paracrine mechanism whereby IL-8 produced in stromal cells can
also affect metastatic properties of PCa.
Prior to work in this dissertation, there has been an increased effort in the
investigation of mechanisms that contribute to bidirectional activities in the progression
of PCa to metastatic disease (234,235). Studies demonstrate that interactions, such as
those between bone marrow stromal cells (BMSCs) and PCa cells, alter gene expression
in PCa cells, but there is limited information regarding how stromal cells alter gene and
protein expression or whether this affects PCa progression (236,237). In PCa, we
know that IL-8 secretory levels and gene expression are elevated as PCa progresses, but
previous studies did not address whether paracrine-mediated contributions of stromal
produced IL-8 affects PCa progression or whether SFK activation is involved.
To investigate the effects of stromal produced IL-8, I utilized the wellestablished and commercially available fibroblast HS5 bone marrow-derived cell line as
representative of the stromal compartment. Torok and Storob et al. report that the
immortalized, non-tumorigenic forming HS5 cells produce high levels of IL-8 and, thus,
are an attractive model to explore the effects of stromal production of IL-8 on PCa
progression (224).
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I first demonstrated that conditioned media from HS5 stromal cells increases
migration and invasion of PCa cells (Figure 20) and through successful knockdown of
IL-8 in HS5 stromal cells (HS5shIL-8), I then demonstrated that HS5 stromal IL-8 is
one factor contributing to increases in migration and invasion of low metastatic PCa
cells (Figure 28-29). It is likely that stromal IL-8 production contributes to the
production of migratory and invasive factors through other cell types. There is evidence
suggesting that IL-8 increases endothelial cell production of MMP-2 and MMP-9,
known invasion markers, and this production correlates with tumor invasiveness (173).
Endothelial cells are involved in the process of trans-endothelial migration of cancer
cells which is correlated with increased metastatic spread of cancer cells (77). Thus,
production of stromal IL-8 could stimulate MMP production in endothelial cells which
increases the migratory and invasive properties of PCa cells. Further studies addressing
whether stromal IL-8-mediated MMP production through SFK activation in PCa cells
affects migration and invasion are needed.
There are also other cell types secreting IL-8 that likely contribute to changes
in PCa progression because PCa is also known to induce an inflammatory
microenvironment whereby IL-8 is also regulated by inflammatory responses (238).
While my current study did not address cancer-induced inflammation, I note that
increased IL-8 secretion in PCa may be due, in part, to the recruitment of inflammatory
cells that also produce IL-8, such as macrophages. Studies show that tumor-infiltrating
macrophages were located near non-small cell lung cancer cells expressing high levels
of IL-8 (239). An interesting question that may be addressed in future studies is what
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role does IL-8 play in prostate cancer-induced inflammation and if it increases
progression of PCa.
In the next set of experiments, I demonstrated that HS5 conditioned media
increases SFK activity in PCa cells, while SFK activity was decreased in the presence
of HS5shIL-8 conditioned media in PCa cells (Figure 25 and 26). I also show that a
feed forward loop exists whereby stromal knockdown of IL-8 decreases Src activity
while SFK inhibition decreases IL-8 activity (Figure 23 and 24). Prior to studies from
this dissertation, investigations studying whether there was an IL-8-mediated SFK
signaling mechanism in stromal cells that contributes to SFK activity in PCa cells had
not been reported. Work from this dissertation demonstrates that IL-8 production by
HS5 stromal cells contributes to increased SFK activity in PCa cells by stromal
production of IL-8 which in turn increases IL-8 production.
Although my results provide a mechanism for stromal IL-8-mediation of SFK
activation in PCa, I do not propose that all of the changes in SFK activity in PCa cells
are mediated by stromal IL-8 because it is likely that other stromal produced factors are
involved in SFK activation. In particular, SFK activation is associated with CXCL-12,
previously referred to as stromal-derived factor 1α and the production of CXCL-12 in
turn affects migration and proliferation (240-242). Further studies are required to
determine if CXCL-12 is relevant in paracrine-mediated events in PCa in an IL-8
independent mechanism. In addition, conditioned media from stromal cells also
produces cytokine factors, such as IL-2 and 3 also increases migration. It would be
interesting to study if these increases were SFK-dependent or independent.
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This study provides a better understanding of how IL-8-mediated SFK
activation contributes to the crosstalk between stromal and PCa cells in PCa
progression. It also suggests that further investigation into the following areas would be
beneficial in understanding PCa progression: 1) investigation of other stromal derived
factors that contribute to PCa progression and 2) exploring how other IL-8 producing
cell models contribute to PCa progression.
The role of HS5 stromal-produced IL-8 in metastatic potential of prostate cancer
In Chapter 5 of this dissertation, I determined that increases in tumor growth
and metastatic potential are, in part, due to HS5 stromal production of IL-8. There were
significant increases in tumor growth, at days 14 and 18, between the PC3:HS5NT cell
combination and the PC3 alone group demonstrating that the tumor-stromal interaction
contributes to tumor growth (Figure 32). I then demonstrate that mice injected with the
combination of PC3 and HS5shIL-8 cells led to tumors that were larger than control but
smaller than the combination of PC3 and HS5NT cells, showing that HS5 stromal IL-8
producing cells contributes to tumor growth. This was further confirmed by the
significant increases seen in the tumor weights of PC3:HS5NT group when compared to
the PC3:HS5shIL-8 group (Table 1). Prior to this investigation, studies investigating
the effects of stromal IL-8 on PCa progression in vivo were limited in scope. It is likely
that the increases in growth observed with PC3:HS5NT group were due to the secretion
and expression of multiple stromal factors, discussed in the previous discussion section.
The next part of this study was to determine if HS5 stromal cells increase the
metastatic potential of PCa cells and whether stromal produced IL-8 is a contributing
factor. I demonstrated that there was a significant increase in metastatic incidence with
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PC3:H5NT stromal cells when compared to PC3 cells (Table 2). There were 4.5
average metastases in the PC3:HS5NT group when compared to 1.5 average metastases
in the PC3 group. The results demonstrate increases in metastatic incidence were due,
in part, to stromal production of IL-8 whereby the PC3:HS5NT group displayed
significantly more metastases than PC3:HS5shIL-8. I demonstrated that stromal
contributions favor increased metastatic potential of PCa, but that, specifically, IL-8
production is one contributing factor.
An interesting finding was the presence of both iliac and renal lymph nodes in
the PC3:HS5NT and PC3:HS5shIL-8 groups whereas the PC3 group only exhibited
iliac lymph node metastases. While it is clear that the tumor-stromal interaction
increased metastases, this variability in metastatic site had not been observed prior to
this study. While the PC3:HS5NT group demonstrated significantly more metastases
relative to PC3:HS5shIL-8 or PC3 groups, there was no significant difference between
renal lymph node metastases in PC3:HS5NT and PC3:HS5shIL-8 groups suggesting
that IL-8 is not responsible for the variability in lymph node metastases. Other factors
that increase metastatic potential need to be investigated. However, this study is
supported by Giannoni et al. demonstrating that the co-injection of PCa cells and
cancer-associated fibroblasts resulted in ‘spontanteous micrometastases’ in the lungs of
mice, not seen in their control groups (235). They suggest that the cancer-associated
fibroblasts increase the aggressiveness of PCa cells creating an opportunity for
metastasis to other less common sites.
To address metastatic potential, my current study uses an orthotopic in vivo
model. While PCa orthotopic mouse models are known to primarily produce lymph
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node metastases, but they do not produce bone metastases (107,244). This is discussed
because PCa preferentially metastasizes to the bone and it would be interesting to
investigate the effects of stromal produced IL-8 in PCa metastasis to the bone. This
could be investigated using one model known to produce bone metastases, the
intracardiac model, whereby intracardiac injection of stromal cells and PCa cells would
be performed. This model could be used to address the specific question of whether
stromal production of IL-8 increases PCa metastasis to the bone.
Overall, this study provides novel in vivo evidence whereby HS5 stromal cells
producing IL-8 increase tumor growth and metastatic potential. It also suggests that
further investigation into the following areas would be beneficial in understanding PCa
progression: 1) examining the roles of other IL-8 producing cells in growth, 2)
investigating stromal IL-8 mediated markers associated with migration and invasion in
metastatic tissue and 3) exploring other mouse models that assess IL-8’s role in
metastasis.
Clinical significance of IL-8 and Src in CRPC
Preclinical studies from our laboratory demonstrated that tumor size and lymph
node metastases were reduced upon dasatanib treatment (107). It was also
demonstrated that after dasatanib treatments in mice with intratibial injections of
prostate tumor cells, PSA levels were decreased significantly as well as bone mineral
density. This result was attenuated with the addition of docetaxel (226). As a result, a
Phase I/II clinical trial with dasatanib+docetaxel trial was completed during my studies
(211). The goal of this study was to determine the efficacy of targeting the epithelial
and bone compartments of PCa with combination docetaxel + dasatanib therapy.
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Response to therapy was determined by PSA levels, but more objectively by the
presence of decreased lesions in radiographic bone scans. Numerous cytokines were
examined, including IL-8. Figure 33 demonstrates that all patients showed response
according to PSA levels, but this response was irrespective of whether there was a
decrease in radiographic response. Nearly all patients showed response according to
IL-8 levels, but, interestingly, this response was increased in patients who did not
respond to treatments. Although this was a very small cohort of samples, studies from
chapter 6 suggest that changes in IL-8 from dasatanib + docetaxel treatment may be
more predictive of response than changes in PSA.
Several reports demonstrate higher levels of IL-8 in serum and tissue of
patients with metastatic disease than in patients without prostate disease or with benign
prostatic hyperplasia (165,244). While my current studies demonstrate that IL-8mediates SFK activity in PCa which contributes to tumor growth and metastatic
potential, the Phase II clinical trial results suggest clinical significance for investigating
IL-8 and Src activity in PCa. It also suggests that by inhibiting SFK activation IL-8
activity is also targeted. In support of this study, Zabransky et al. provides another
study demonstrating that lenalidomide, a thalidomide analog, treatments increased
numerous cytokine levels in men with biochemically recurrent PCa, except for one
cytokine IL-8. Similar to studies with dasatanib, but through a different therapeutic
strategy, this study demonstrates that IL-8 levels were decreased in patients who
responded while IL-8 levels were increased in those who had progressive disease (169).
These results suggest that there is therapeutic benefit in targeting SFK/IL-8 signaling
and that there may be an advantage to using IL-8 as a biomarker of metastatic disease.
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Currently, there is a Phase I clinical trial assessing the safety and efficacy of
lenalidomide + docetaxel treatments in men with metastatic CRPC. A Phase III study
assessing the effects of dasatanib in metastatic CRPC has been completed with results
pending. As a result, the assessment of IL-8 levels in responding and non-responding
patients may be crucial in understanding how the inhibition of SFK/IL-8 signaling
affects metastatic CRPC.
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Figure 34 Schematic Representation of IL-8-mediated SFK Activity in Tumor and
Stromal Cells
The proposed mechanism shows that IL-8 increases Src activity in low metastatic
prostate cancer cells and in turn IL-8 is produced further stimulating Src activation
demonstrating a feed forward loop that increases metastatic properties of PCa cells.
However, the IL-8/SFK signaling axis in the prostate cancer cells is not completely
sufficient in increasing their metastatic potential, but, rather, stromal IL-8 production is
contributes to metastatic potential and growth of PCa cells through a paracrine
mechanism. Targeting SFK acitivity by dasatanib will likely decrease SFK activity in
the stromal and prostate cancer cells decreasing production of IL-8 and inhibit
metastatic spread of PCa.
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Summary/Current Perspectives
Collectively, this dissertation demonstrates that: 1) IL-8 mediates SFK activity
in the tumor through a feed forward mechanism, 2) a stromal IL-8-mediated paracrine
mechanism increases SFK activity and metastatic properties of PCa an 3) IL-8 is one
factor in the tumor-stromal interaction contributing to tumor growth and metastatic
potential (Figure 34). Thus, I hypothesized that IL-8 is one factor mediating increases
in tumor growth and metastatic potential of PCa through SFK activation.
This study demonstrates that IL-8 increases Src activity in PCa cells, but there
is increasing evidence suggesting the role of other SFK members in PCa progression.
Of the SFK members, there is evidence demonstrating a role for Lyn in PCa
progression, but there is increasing evidence suggesting Fyn plays a putative role in PCa
progression (245). This is important because as we begin to understand how Fyn
contributes to PCa we can explore signaling pathways associated with its expression.
Park et al. suggests that SFK members have differential roles in PCa, so it likely that
Fyn’s contributions to biological activities of PCa are not exactly the same as other SFK
members. As such, the role Fyn plays in the metastatic process should be explored. In
addition, it would be interesting to investigate whether Fyn increases the metastatic
potential of PCa through an IL-8-mediated mechanism. While studies investigating this
would be useful in better understanding how activation of SFKs contribute to the
metastatic process, it would also be beneficial in delineating why SFK inhibitors, such
as dasatanib, are effective in decreasing tumor growth and metastatic potential.
There are multiple studies that have investigated therapies that target signaling
pathways involved with metastatic PCa, outlined in Introduction. While preclinical
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models of melanoma and other cancers demonstrated successful inhibition of metastasis
by blocking IL-8 using ABX-IL8 the fully human neutralizing antibody against IL-8,
this therapy was ineffective in clinical trials as a single therapy. Studies supporting this
demonstrate that therapies, such as dacarbazine, elicit cytotoxic effects which attenuated
IL-8 and VEGF levels. Further studies suggested that a combination therapy, including
dacarbazine and ABX-IL8, may be beneficial by abolishing IL-8 production increasing
the effectiveness of dacarbazine (246). This implies that the use of IL-8 neutralizing
antibodies would diminish the drug-induced IL-8 response increasing the effectiveness
of drug therapies.
As it relates to prostate cancer, Wilson et al. demonstrates that oxaliplatin
induces IL-8 production in PCa cells which stabilizes the IL-8-induced changes to PCa
progression. In addition, this report demonstrates that the combination of oxaliplatin
and the depletion of the secondary IL-8 receptor, CXCR2, increases anti-proliferative
signaling mechanisms (247). This suggests that the receptors are also important targets.
As a result, the development of small molecule inhibitors targeting CXCR1 and CXCR2
are being investigated, but in vivo studies are also needed to identify their role as a
therapeutic strategy (247,248). Future studies would be needed to determine if the
combination of IL-8 neutralizing antibody therapies and current drug therapies increases
the effectiveness of drug therapies by diminishing IL-8-induced changes to PCa
progression.
In addition, these studies also beg the question of the usefulness of IL-8 as a
target or as a biomarker for response. Chapter 6 of this thesis demonstrates, in a small
cohort of patients, that IL-8 levels are decreased in patients who respond to
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docetaxel+dasatanib, while in non-responding patients IL-8 levels are still increased.
The IL-8-mediated SFK axis is perturbed through SFK inhibition in responding
metastatic CRPC patients. It is likely that by targeting SFK activation IL-8 will be
inhibited providing a targetable signaling pathway that exists not only in the tumor but
in the microenvironment as well as decreasing metastatic disease. In addition, the
sustained high IL-8 levels in patients who did not respond to treatments, such as those
in the Phase I/II dasatanib trial of chapter 6, provides reasoning for the use of IL-8 as a
marker of response to treatment modalities inhibiting SFKs. While this provides strong
implications for IL-8 as a marker of response for bone metastatic disease in the Phase
III clinical trials, it is possible that in a larger sample of patients there may not be
comparable results. In this context, IL-8 may be useful in assessing disease that has
metastasized to a primary metastatic site, such as lymph node. Evidence from my in
vivo experiments demonstrates that IL-8 is also involved in PCa metastases to the
lymph nodes. The use of therapies inhibiting SFKs can provide benefit for a subset of
patients that have lymph node metastases by potentially decreasing spread to the bone.
These studies suggest: 1) that investigating the role of IL-8 and Fyn in PCa
progression may be useful in understanding SFK activities in the metastatic process, 2)
that therapies targeting PCa through SFK inhibition, such as dasatanib, subsequently
decreasing IL-8 levels are needed, 3) studies addressing the significance of the IL-8
receptors in metastatic disease and as a therapeutic strategy will be beneficial and 3)
that IL-8 may serve as a predictor of disease progression.
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Conclusions
Aberrant activation of SFK activity and overexpression and production of IL-8
have been frequently associated with PCa progression. The regulation of IL-8 by SFK
activity has been implicated as a mechanism involved in PCa progression. In addition,
the production of IL-8 by tumor-associated cells, such as stromal cells, contributes to
tumor progression.

This dissertation demonstrates that a feed forward loop exists

whereby IL-8 increases SFK activity which in turn increases SFK in PCa cells and this
contributes to migration and invasion of PCa. In addition, a paracrine loop exists
whereby stromal production of IL-8 increases SFK activity and inhibition of stromal IL8 decreases SFK activity to baseline levels which was also seen in migration and
invasion of PCa cells. The tumor-stromal interaction increased tumor growth and
metastases while these increases were decreased upon inhibition of stromal IL-8
demonstrating that stromal IL-8 is one major contributing factor in tumor growth and
metastatic potential. My study establishes an IL-8-mediated mechanism in the
activation of SFKs in PCa. I also establish that stromal IL-8 contributes to metastatic
properties in PCa which are involved in increasing tumor growth and metastatic
potential in PCa. This study provides evidence that a feed forward loop whereby IL-8
increases SFK activity exists providing unique evidence that IL-8 mediation of SFK
activity involves Src. The paracrine role of stromal IL-8 in vitro and in tumor growth
and metastatic potential also provides new insights into how IL-8 production by tumorassociated stromal cells contributes to the metastatic process.
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